Utah 2025 Regular Session

Utah House Bill HB0543 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	02-21 16:04 H.B. 543
2	2	1
3	3	Controlled Substance Licensing Amendments
4	4	2025 GENERAL SESSION
5	5	STATE OF UTAH
6	6	Chief Sponsor: Raymond P. Ward
7	7	Senate Sponsor:
8	8	2
9	9
10	10	3
11	11	LONG TITLE
12	12	4
13	13	General Description:
14	14	5
15	15	This bill makes changes concerning the licensing requirements related to controlled
16	16	6
17	17	substances.
18	18	7
19	19	Highlighted Provisions:
20	20	8
21	21	This bill:
22	22	9
23	23	▸ defines terms and amends definitions;
24	24	10
25	25	▸ requires the Division of Professional Licensing to create a controlled substance
26	26	11
27	27	certification for certain practitioners;
28	28	12
29	29	▸ provides that a practitioner may not distribute, dispense, or administer a controlled
30	30	13
31	31	substance without a controlled substance certification;
32	32	14
33	33	▸ prescribes requirements for certified practitioners;
34	34	15
35	35	▸ updates provisions of the Utah Controlled Substances Act to reflect the creation of a
36	36	16
37	37	controlled substance certification;
38	38	17
39	39	▸ repeals provisions relating to a controlled substance license; and
40	40	18
41	41	▸ makes technical and conforming changes.
42	42	19
43	43	Money Appropriated in this Bill:
44	44	20
45	45	None
46	46	21
47	47	Other Special Clauses:
48	48	22
49	49	This bill provides a special effective date.
50	50	23
51	51	Utah Code Sections Affected:
52	52	24
53	53	AMENDS:
54	54	25
55	55	26B-4-513 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapter 507
56	56	26
57	57	58-37-2 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapter 35
58	58	27
59	59	58-37-4 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapter 298
60	60	28
61	61	58-37-5.5 (Effective 07/01/25), as last amended by Laws of Utah 2008, Chapter 250
62	62	29
63	63	58-37-6 (Effective 07/01/25), as last amended by Laws of Utah 2022, Chapter 415
64	64	30
65	65	58-37-8 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapter 105
66	66	H.B. 543 H.B. 543 02-21 16:04
67	67	31
68	68	58-37-10 (Effective 07/01/25), as last amended by Laws of Utah 2013, Chapter 278
69	69	32
70	70	58-37-15 (Effective 07/01/25), as enacted by Laws of Utah 1971, Chapter 145
71	71	33
72	72	58-37-19 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapter 381
73	73	34
74	74	58-37-22 (Effective 07/01/25), as last amended by Laws of Utah 2023, Chapter 329
75	75	35
76	76	58-37b-2 (Effective 07/01/25), as last amended by Laws of Utah 2010, Chapter 64
77	77	36
78	78	58-37f-201 (Effective 07/01/25), as last amended by Laws of Utah 2023, Chapters 329,
79	79	37
80	80	415
81	81	38
82	82	58-37f-303 (Effective 07/01/25), as last amended by Laws of Utah 2021, Chapter 340
83	83	39
84	84	58-37f-304 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapter 507
85	85	40
86	86	58-37f-502 (Effective 07/01/25), as last amended by Laws of Utah 2010, Chapter 391
87	87	41
88	88	and renumbered and amended by Laws of Utah 2010, Chapter 287
89	89	42
90	90	58-37f-702 (Effective 07/01/25), as last amended by Laws of Utah 2023, Chapter 329
91	91	43
92	92	58-37f-703 (Effective 07/01/25), as last amended by Laws of Utah 2023, Chapter 415
93	93	44
94	94	63I-1-258 (Effective 07/01/25), as last amended by Laws of Utah 2024, Third Special
95	95	45
96	96	Session, Chapter 5
97	97	46
98	98	76-5-102.1 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapter 197
99	99	47
100	100	76-5-207 (Effective 07/01/25), as last amended by Laws of Utah 2024, Chapters 153,
101	101	48
102	102	208 and 381
103	103	49
104	104	ENACTS:
105	105	50
106	106	58-1-605 (Effective 05/07/25), Utah Code Annotated 1953
107	107	51
108	108	REPEALS:
109	109	52
110	110	26B-3-131 (Effective 07/01/25), as renumbered and amended by Laws of Utah 2023,
111	111	53
112	112	Chapter 306
113	113	54
114	114	49-20-416 (Effective 07/01/25), as enacted by Laws of Utah 2017, Chapter 180
115	115	55
116	116	58-37-6.5 (Effective 07/01/25), as last amended by Laws of Utah 2023, Chapter 329
117	117	56
118	118
119	119	57
120	120	Be it enacted by the Legislature of the state of Utah:
121	121	58
122	122	Section 1. Section 26B-4-513 is amended to read:
123	123	59
124	124	26B-4-513 (Effective 07/01/25). Coprescription guidelines.
125	125	60
126	126	(1) As used in this section:
127	127	61
128	128	(a) ["Controlled substance prescriber" means the same as that term is defined in Section
129	129	62
130	130	58-37-6.5] "Certified practitioner" means the same as that term is defined in Section
131	131	63
132	132	58-1-605.
133	133	64
134	134	(b) "Coprescribe" means to issue a prescription for an opiate antagonist with a
135	135	- 2 - 02-21 16:04 H.B. 543
136	136	65
137	137	prescription for an opiate.
138	138	66
139	139	(2) The department shall, in consultation with the Medical Licensing Board created in
140	140	67
141	141	Section 58-67-201, and the Division of Professional Licensing created in Section
142	142	68
143	143	58-1-103, establish by rule, made in accordance with Title 63G, Chapter 3, Utah
144	144	69
145	145	Administrative Rulemaking Act, scientifically based guidelines for controlled substance
146	146	70
147	147	prescribers to coprescribe an opiate antagonist to a patient.
148	148	71
149	149	Section 2. Section 58-1-605 is enacted to read:
150	150	72
151	151
152	152	Part 6. Unique Training and Certification
153	153	73
154	154	58-1-605 (Effective 05/07/25). Controlled substance certification.
155	155	74
156	156	(1) As used in this section:
157	157	75
158	158	(a) "Administer" means the same as that term is defined in Section 58-37-2.
159	159	76
160	160	(b) "Certified practitioner" means a practitioner who has a controlled substance
161	161	77
162	162	certification.
163	163	78
164	164	(c) "Controlled substance" means the same as that term is defined in Section 58-37-2.
165	165	79
166	166	(d) "Controlled substance certification" means a certification issued by the division to
167	167	80
168	168	certify that a practitioner has an active DEA registration.
169	169	81
170	170	(e) "DEA registration" means a registration issued by the federal Drug Enforcement
171	171	82
172	172	Administration.
173	173	83
174	174	(f) "Dispense" means the same as that term is defined in Section 58-37-2.
175	175	84
176	176	(g) "Distribute" means the same as that term is defined in Section 58-37-2.
177	177	85
178	178	(h) "Practitioner" means an individual licensed under Title 58, Occupations and
179	179	86
180	180	Professions, whose scope of practice includes the ability to distribute, dispense, or
181	181	87
182	182	administer a controlled substance.
183	183	88
184	184	(i) "Prescribe" means the same as that term is defined in Section 58-37-2.
185	185	89
186	186	(2) The division shall create a controlled substance certification on or before June 30, 2025.
187	187	90
188	188	(3) Beginning July 1, 2025:
189	189	91
190	190	(a) a practitioner who does not have a license issued by the division to manufacture,
191	191	92
192	192	produce, distribute, prescribe, dispense, administer, conduct research with, or
193	193	93
194	194	perform laboratory analysis upon controlled substances, may not distribute, dispense,
195	195	94
196	196	prescribe, or administer a controlled substance without a controlled substance
197	197	95
198	198	certification; and
199	199	96
200	200	(b) a practitioner who has a current license issued by the division to manufacture,
201	201	97
202	202	produce, distribute, prescribe, dispense, administer, conduct research with, or
203	203	98
204	204	perform laboratory analysis upon controlled substances:
205	205	- 3 - H.B. 543 02-21 16:04
206	206	99
207	207	(i) may continue to act within the scope of that license as long as that license is active
208	208	100
209	209	and in good standing; and
210	210	101
211	211	(ii) after the practitioner's current license expires or is revoked, surrendered, or
212	212	102
213	213	suspended, may not distribute, dispense, prescribe, or administer a controlled
214	214	103
215	215	substance without a controlled substance certification.
216	216	104
217	217	(4) Except as provided in Subsection (3), a practitioner may act within the practitioner's
218	218	105
219	219	scope of practice regardless of whether the practitioner has a controlled substance
220	220	106
221	221	certification.
222	222	107
223	223	(5) The division may issue an original controlled substance certification:
224	224	108
225	225	(a) to an individual concurrent with the individual's original license under Title 58,
226	226	109
227	227	Occupations and Professions;
228	228	110
229	229	(b) to a practitioner at the time the division renews the practitioner's license under Title
230	230	111
231	231	58, Occupations and Professions; or
232	232	112
233	233	(c) to a practitioner at any other time if the practitioner submits an application in a form
234	234	113
235	235	prescribed by the division.
236	236	114
237	237	(6) The division shall issue an original or renewal controlled substance certification to an
238	238	115
239	239	applicant who:
240	240	116
241	241	(a) has a current DEA registration; and
242	242	117
243	243	(b) complies with or satisfies any other requirements or qualifications created by the
244	244	118
245	245	division in rules established pursuant to Subsection (9), including the requirements
246	246	119
247	247	described in Subsection (7).
248	248	120
249	249	(7)(a) The division shall, by rule established pursuant to Subsection (9), require certified
250	250	121
251	251	practitioners to complete 3.5 continuing education hours per licensing period in one
252	252	122
253	253	or more controlled substance prescribing classes.
254	254	123
255	255	(b) A controlled substance prescribing class required pursuant to Subsection (7)(a) does
256	256	124
257	257	not increase the total number of state-required continuing professional education
258	258	125
259	259	hours required for prescriber licensing.
260	260	126
261	261	(8) The division shall issue each controlled substance certification in accordance with a
262	262	127
263	263	three-year renewal cycle.
264	264	128
265	265	(9) The division may establish rules, in accordance with Title 63G, Chapter 3, Utah
266	266	129
267	267	Administrative Rulemaking Act, to implement this section.
268	268	130
269	269	Section 3. Section 58-37-2 is amended to read:
270	270	131
271	271	58-37-2 (Effective 07/01/25). Definitions.
272	272	132
273	273	(1) As used in this chapter:
274	274	- 4 - 02-21 16:04 H.B. 543
275	275	133
276	276	(a) "Administer" means the direct application of a controlled substance, whether by
277	277	134
278	278	injection, inhalation, ingestion, or any other means, to the body of a patient or
279	279	135
280	280	research subject by:
281	281	136
282	282	(i) a practitioner or, in the practitioner's presence, by the practitioner's authorized
283	283	137
284	284	agent; or
285	285	138
286	286	(ii) the patient or research subject at the direction and in the presence of the
287	287	139
288	288	practitioner.
289	289	140
290	290	(b) "Agent" means an authorized person who acts on behalf of or at the direction of a
291	291	141
292	292	manufacturer, distributor, or practitioner but does not include a motor carrier, public
293	293	142
294	294	warehouseman, or employee of any of them.
295	295	143
296	296	(c) "Certified practitioner" means a practitioner with a valid controlled substance
297	297	144
298	298	certification.
299	299	145
300	300	[(c)] (d) "Consumption" means ingesting or having any measurable amount of a
301	301	146
302	302	controlled substance in a person's body, but this Subsection [(1)(c)] (1)(d) does not
303	303	147
304	304	include the metabolite of a controlled substance.
305	305	148
306	306	[(d)] (e) "Continuing criminal enterprise" means any individual, sole proprietorship,
307	307	149
308	308	partnership, corporation, business trust, association, or other legal entity, and any
309	309	150
310	310	union or groups of individuals associated in fact although not a legal entity, and
311	311	151
312	312	includes illicit as well as licit entities created or maintained for the purpose of
313	313	152
314	314	engaging in conduct which constitutes the commission of episodes of activity made
315	315	153
316	316	unlawful by Chapter 37, Utah Controlled Substances Act, Chapter 37a, Utah Drug
317	317	154
318	318	Paraphernalia Act, Chapter 37b, Imitation Controlled Substances Act, Chapter 37c,
319	319	155
320	320	Utah Controlled Substance Precursor Act, or Chapter 37d, Clandestine Drug Lab Act,
321	321	156
322	322	which episodes are not isolated, but have the same or similar purposes, results,
323	323	157
324	324	participants, victims, methods of commission, or otherwise are interrelated by
325	325	158
326	326	distinguishing characteristics. Taken together, the episodes shall demonstrate
327	327	159
328	328	continuing unlawful conduct and be related either to each other or to the enterprise.
329	329	160
330	330	[(e)] (f) "Control" means to add, remove, or change the placement of a drug, substance,
331	331	161
332	332	or immediate precursor under Section 58-37-3.
333	333	162
334	334	[(f)] (g)(i) "Controlled substance" means a drug or substance:
335	335	163
336	336	(A) included in Schedules I, II, III, IV, or V of Section 58-37-4;
337	337	164
338	338	(B) included in Schedules I, II, III, IV, or V of the federal Controlled Substances
339	339	165
340	340	Act, Title II, P.L. 91-513;
341	341	166
342	342	(C) that is a controlled substance analog; or
343	343	- 5 - H.B. 543 02-21 16:04
344	344	167
345	345	(D) listed in Section 58-37-4.2.
346	346	168
347	347	(ii) "Controlled substance" does not include:
348	348	169
349	349	(A) distilled spirits, wine, or malt beverages, as those terms are defined in Title
350	350	170
351	351	32B, Alcoholic Beverage Control Act;
352	352	171
353	353	(B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment,
354	354	172
355	355	or prevention of disease in human or other animals, which contains ephedrine,
356	356	173
357	357	pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is
358	358	174
359	359	lawfully purchased, sold, transferred, or furnished as an over-the-counter
360	360	175
361	361	medication without prescription; or
362	362	176
363	363	(C) dietary supplements, vitamins, minerals, herbs, or other similar substances
364	364	177
365	365	including concentrates or extracts, which:
366	366	178
367	367	(I) are not otherwise regulated by law; and
368	368	179
369	369	(II) may contain naturally occurring amounts of chemical or substances listed
370	370	180
371	371	in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah
372	372	181
373	373	Administrative Rulemaking Act.
374	374	182
375	375	[(g)] (h)(i) "Controlled substance analog" means:
376	376	183
377	377	(A) a substance the chemical structure of which is substantially similar to the
378	378	184
379	379	chemical structure of a controlled substance listed in Schedules I and II of
380	380	185
381	381	Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and
382	382	186
383	383	II of the federal Controlled Substances Act, Title II, P.L. 91-513;
384	384	187
385	385	(B) a substance which has a stimulant, depressant, or hallucinogenic effect on the
386	386	188
387	387	central nervous system substantially similar to the stimulant, depressant, or
388	388	189
389	389	hallucinogenic effect on the central nervous system of controlled substances
390	390	190
391	391	listed in Schedules I and II of Section 58-37-4, substances listed in Section
392	392	191
393	393	58-37-4.2, or substances listed in Schedules I and II of the federal Controlled
394	394	192
395	395	Substances Act, Title II, P.L. 91-513; or
396	396	193
397	397	(C) A substance which, with respect to a particular individual, is represented or
398	398	194
399	399	intended to have a stimulant, depressant, or hallucinogenic effect on the central
400	400	195
401	401	nervous system substantially similar to the stimulant, depressant, or
402	402	196
403	403	hallucinogenic effect on the central nervous system of controlled substances
404	404	197
405	405	listed in Schedules I and II of Section 58-37-4, substances listed in Section
406	406	198
407	407	58-37-4.2, or substances listed in Schedules I and II of the federal Controlled
408	408	199
409	409	Substances Act, Title II, P.L. 91-513.
410	410	200
411	411	(ii) "Controlled substance analog" does not include:
412	412	- 6 - 02-21 16:04 H.B. 543
413	413	201
414	414	(A) a controlled substance currently scheduled in Schedules I through V of
415	415	202
416	416	Section 58-37-4;
417	417	203
418	418	(B) a substance for which there is an approved new drug application;
419	419	204
420	420	(C) a substance with respect to which an exemption is in effect for investigational
421	421	205
422	422	use by a particular person under Section 505 of the Food, Drug, and Cosmetic
423	423	206
424	424	Act, 21 U.S.C. 355, to the extent the conduct with respect to the substance is
425	425	207
426	426	permitted by the exemption;
427	427	208
428	428	(D) any substance to the extent not intended for human consumption before an
429	429	209
430	430	exemption takes effect with respect to the substance;
431	431	210
432	432	(E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment,
433	433	211
434	434	or prevention of disease in man or other animals, which contains ephedrine,
435	435	212
436	436	pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is
437	437	213
438	438	lawfully purchased, sold, transferred, or furnished as an over-the-counter
439	439	214
440	440	medication without prescription; or
441	441	215
442	442	(F) dietary supplements, vitamins, minerals, herbs, or other similar substances
443	443	216
444	444	including concentrates or extracts, which are not otherwise regulated by law,
445	445	217
446	446	which may contain naturally occurring amounts of chemical or substances
447	447	218
448	448	listed in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah
449	449	219
450	450	Administrative Rulemaking Act.
451	451	220
452	452	(i) "Controlled substance certification" means a certification issued by the division
453	453	221
454	454	pursuant to Section 58-1-605.
455	455	222
456	456	[(h)] (j)(i) "Conviction" means a determination of guilt by verdict, whether jury or
457	457	223
458	458	bench, or plea, whether guilty or no contest, for any offense proscribed by:
459	459	224
460	460	(A) Chapter 37, Utah Controlled Substances Act;
461	461	225
462	462	(B) Chapter 37a, Utah Drug Paraphernalia Act;
463	463	226
464	464	(C) Chapter 37b, Imitation Controlled Substances Act;
465	465	227
466	466	(D) Chapter 37c, Utah Controlled Substance Precursor Act; or
467	467	228
468	468	(E) Chapter 37d, Clandestine Drug Lab Act; or
469	469	229
470	470	(ii) for any offense under the laws of the United States and any other state which, if
471	471	230
472	472	committed in this state, would be an offense under:
473	473	231
474	474	(A) Chapter 37, Utah Controlled Substances Act;
475	475	232
476	476	(B) Chapter 37a, Utah Drug Paraphernalia Act;
477	477	233
478	478	(C) Chapter 37b, Imitation Controlled Substances Act;
479	479	234
480	480	(D) Chapter 37c, Utah Controlled Substance Precursor Act; or
481	481	- 7 - H.B. 543 02-21 16:04
482	482	235
483	483	(E) Chapter 37d, Clandestine Drug Lab Act.
484	484	236
485	485	[(i)] (k) "Counterfeit substance" means:
486	486	237
487	487	(i) any controlled substance or container or labeling of any controlled substance that:
488	488	238
489	489	(A) without authorization bears the trademark, trade name, or other identifying
490	490	239
491	491	mark, imprint, number, device, or any likeness of them, of a manufacturer,
492	492	240
493	493	distributor, or dispenser other than the person or persons who in fact
494	494	241
495	495	manufactured, distributed, or dispensed the substance which falsely purports to
496	496	242
497	497	be a controlled substance distributed by any other manufacturer, distributor, or
498	498	243
499	499	dispenser; and
500	500	244
501	501	(B) a reasonable person would believe to be a controlled substance distributed by
502	502	245
503	503	an authorized manufacturer, distributor, or dispenser based on the appearance
504	504	246
505	505	of the substance as described under Subsection [(1)(i)(i)(A)] (1)(k)(i)(A) or the
506	506	247
507	507	appearance of the container of that controlled substance; or
508	508	248
509	509	(ii) any substance other than under Subsection [(1)(i)(i)] (1)(k)(i) that:
510	510	249
511	511	(A) is falsely represented to be any legally or illegally manufactured controlled
512	512	250
513	513	substance; and
514	514	251
515	515	(B) a reasonable person would believe to be a legal or illegal controlled substance.
516	516	252
517	517	[(j)] (l) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a
518	518	253
519	519	controlled substance or a listed chemical, whether or not an agency relationship exists.
520	520	254
521	521	[(k)] (m) "Department" means the Department of Commerce.
522	522	255
523	523	[(l)] (n) "Depressant or stimulant substance" means:
524	524	256
525	525	(i) a drug which contains any quantity of barbituric acid or any of the salts of
526	526	257
527	527	barbituric acid;
528	528	258
529	529	(ii) a drug which contains any quantity of:
530	530	259
531	531	(A) amphetamine or any of its optical isomers;
532	532	260
533	533	(B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or
534	534	261
535	535	(C) any substance which the Secretary of Health and Human Services or the
536	536	262
537	537	Attorney General of the United States after investigation has found and by
538	538	263
539	539	regulation designated habit-forming because of its stimulant effect on the
540	540	264
541	541	central nervous system;
542	542	265
543	543	(iii) lysergic acid diethylamide; or
544	544	266
545	545	(iv) any drug which contains any quantity of a substance which the Secretary of
546	546	267
547	547	Health and Human Services or the Attorney General of the United States after
548	548	268
549	549	investigation has found to have, and by regulation designated as having, a
550	550	- 8 - 02-21 16:04 H.B. 543
551	551	269
552	552	potential for abuse because of its depressant or stimulant effect on the central
553	553	270
554	554	nervous system or its hallucinogenic effect.
555	555	271
556	556	[(m)] (o) "Dispense" means the delivery of a controlled substance by a pharmacist to an
557	557	272
558	558	ultimate user pursuant to the lawful order or prescription of a practitioner, and
559	559	273
560	560	includes distributing to, leaving with, giving away, or disposing of that substance as
561	561	274
562	562	well as the packaging, labeling, or compounding necessary to prepare the substance
563	563	275
564	564	for delivery.
565	565	276
566	566	[(n)] (p) "Dispenser" means a pharmacist who dispenses a controlled substance.
567	567	277
568	568	[(o)] (q) "Distribute" means to deliver other than by administering or dispensing a
569	569	278
570	570	controlled substance or a listed chemical.
571	571	279
572	572	[(p)] (r) "Distributor" means a person who distributes controlled substances.
573	573	280
574	574	[(q)] (s) "Division" means the Division of Professional Licensing created in Section
575	575	281
576	576	58-1-103.
577	577	282
578	578	[(r)] (t)(i) "Drug" means:
579	579	283
580	580	(A) a substance recognized in the official United States Pharmacopoeia, Official
581	581	284
582	582	Homeopathic Pharmacopoeia of the United States, or Official National
583	583	285
584	584	Formulary, or any supplement to any of them, intended for use in the
585	585	286
586	586	diagnosis, cure, mitigation, treatment, or prevention of disease in humans or
587	587	287
588	588	animals;
589	589	288
590	590	(B) a substance that is required by any applicable federal or state law or rule to be
591	591	289
592	592	dispensed by prescription only or is restricted to administration by practitioners
593	593	290
594	594	only;
595	595	291
596	596	(C) a substance other than food intended to affect the structure or any function of
597	597	292
598	598	the body of humans or other animals; and
599	599	293
600	600	(D) substances intended for use as a component of any substance specified in
601	601	294
602	602	Subsections [(1)(r)(i)(A)] (1)(t)(i)(A), (B), and (C).
603	603	295
604	604	(ii) "Drug" does not include dietary supplements.
605	605	296
606	606	[(s)] (u) "Drug dependent person" means any individual who unlawfully and habitually
607	607	297
608	608	uses any controlled substance to endanger the public morals, health, safety, or
609	609	298
610	610	welfare, or who is so dependent upon the use of controlled substances as to have lost
611	611	299
612	612	the power of self-control with reference to the individual's dependency.
613	613	300
614	614	[(t)] (v) "Food" means:
615	615	301
616	616	(i) any nutrient or substance of plant, mineral, or animal origin other than a drug as
617	617	302
618	618	specified in this chapter, and normally ingested by human beings; and
619	619	- 9 - H.B. 543 02-21 16:04
620	620	303
621	621	(ii) foods for special dietary uses as exist by reason of a physical, physiological,
622	622	304
623	623	pathological, or other condition including but not limited to the conditions of
624	624	305
625	625	disease, convalescence, pregnancy, lactation, allergy, hypersensitivity to food,
626	626	306
627	627	underweight, and overweight; uses for supplying a particular dietary need which
628	628	307
629	629	exist by reason of age including but not limited to the ages of infancy and
630	630	308
631	631	childbirth, and also uses for supplementing and for fortifying the ordinary or
632	632	309
633	633	unusual diet with any vitamin, mineral, or other dietary property for use of a food.
634	634	310
635	635	Any particular use of a food is a special dietary use regardless of the nutritional
636	636	311
637	637	purposes.
638	638	312
639	639	[(u)] (w) "Immediate precursor" means a substance which the Attorney General of the
640	640	313
641	641	United States has found to be, and by regulation designated as being, the principal
642	642	314
643	643	compound used or produced primarily for use in the manufacture of a controlled
644	644	315
645	645	substance, or which is an immediate chemical intermediary used or likely to be used
646	646	316
647	647	in the manufacture of a controlled substance, the control of which is necessary to
648	648	317
649	649	prevent, curtail, or limit the manufacture of the controlled substance.
650	650	318
651	651	[(v)] (x) "Indian" means a member of an Indian tribe.
652	652	319
653	653	[(w)] (y) "Indian religion" means any religion:
654	654	320
655	655	(i) the origin and interpretation of which is from within a traditional Indian culture or
656	656	321
657	657	community; and
658	658	322
659	659	(ii) which is practiced by Indians.
660	660	323
661	661	[(x)] (z) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or
662	662	324
663	663	community of Indians, including any Alaska Native village, which is legally
664	664	325
665	665	recognized as eligible for and is consistent with the special programs, services, and
666	666	326
667	667	entitlements provided by the United States to Indians because of their status as
668	668	327
669	669	Indians.
670	670	328
671	671	[(y)] (aa) "Manufacture" means the production, preparation, propagation, compounding,
672	672	329
673	673	or processing of a controlled substance, either directly or indirectly by extraction
674	674	330
675	675	from substances of natural origin, or independently by means of chemical synthesis
676	676	331
677	677	or by a combination of extraction and chemical synthesis.
678	678	332
679	679	[(z)] (bb) "Manufacturer" includes any person who packages, repackages, or labels any
680	680	333
681	681	container of any controlled substance, except pharmacists who dispense or compound
682	682	334
683	683	prescription orders for delivery to the ultimate consumer.
684	684	335
685	685	[(aa)] (cc)(i) "Marijuana" means all species of the genus cannabis and all parts of the
686	686	336
687	687	genus, whether growing or not, including:
688	688	- 10 - 02-21 16:04 H.B. 543
689	689	337
690	690	(A) seeds;
691	691	338
692	692	(B) resin extracted from any part of the plant, including the resin extracted from
693	693	339
694	694	the mature stalks;
695	695	340
696	696	(C) every compound, manufacture, salt, derivative, mixture, or preparation of the
697	697	341
698	698	plant, seeds, or resin;
699	699	342
700	700	(D) any synthetic equivalents of the substances contained in the plant cannabis
701	701	343
702	702	sativa or any other species of the genus cannabis which are chemically
703	703	344
704	704	indistinguishable and pharmacologically active; and
705	705	345
706	706	(E) any component part or cannabinoid extracted or isolated from the plant,
707	707	346
708	708	including extracted or isolated tetrahydrocannabinols.
709	709	347
710	710	(ii) "Marijuana" does not include:
711	711	348
712	712	(A) the mature stalks of the plant;
713	713	349
714	714	(B) fiber produced from the stalks;
715	715	350
716	716	(C) oil or cake made from the seeds of the plant;
717	717	351
718	718	(D) except as provided in Subsection [(1)(aa)(i)] (1)(cc)(i), any other compound,
719	719	352
720	720	manufacture, salt, derivative, mixture, or preparation of the mature stalks,
721	721	353
722	722	fiber, oil or cake;
723	723	354
724	724	(E) the sterilized seed of the plant which is incapable of germination;
725	725	355
726	726	(F) any compound, mixture, or preparation approved by the federal Food and
727	727	356
728	728	Drug Administration under the federal Food, Drug, and Cosmetic Act, 21
729	729	357
730	730	U.S.C. Sec. 301 et seq. that is not listed in a schedule of controlled substances
731	731	358
732	732	in Section 58-37-4 or in the federal Controlled Substances Act, Title II, P.L.
733	733	359
734	734	91-513; or
735	735	360
736	736	(G) transportable industrial hemp concentrate as that term is defined in Section
737	737	361
738	738	4-41-102.
739	739	362
740	740	[(bb)] (dd) "Money" means officially issued coin and currency of the United States or
741	741	363
742	742	any foreign country.
743	743	364
744	744	[(cc)] (ee) "Narcotic drug" means any of the following, whether produced directly or
745	745	365
746	746	indirectly by extraction from substances of vegetable origin, or independently by
747	747	366
748	748	means of chemical synthesis, or by a combination of extraction and chemical
749	749	367
750	750	synthesis:
751	751	368
752	752	(i) opium, coca leaves, and opiates;
753	753	369
754	754	(ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves,
755	755	370
756	756	or opiates;
757	757	- 11 - H.B. 543 02-21 16:04
758	758	371
759	759	(iii) opium poppy and poppy straw; or
760	760	372
761	761	(iv) a substance, and any compound, manufacture, salt, derivative, or preparation of
762	762	373
763	763	the substance, which is chemically identical with any of the substances referred to
764	764	374
765	765	in Subsection [(1)(cc)(i)] (1)(ee)(i), (ii), or (iii), except narcotic drug does not
766	766	375
767	767	include decocainized coca leaves or extracts of coca leaves which do not contain
768	768	376
769	769	cocaine or ecgonine.
770	770	377
771	771	[(dd)] (ff) "Negotiable instrument" means documents, containing an unconditional
772	772	378
773	773	promise to pay a sum of money, which are legally transferable to another party by
774	774	379
775	775	endorsement or delivery.
776	776	380
777	777	[(ee)] (gg) "Opiate" means any drug or other substance having an addiction-forming or
778	778	381
779	779	addiction-sustaining liability similar to morphine or being capable of conversion into
780	780	382
781	781	a drug having addiction-forming or addiction-sustaining liability.
782	782	383
783	783	[(ff)] (hh) "Opium poppy" means the plant of the species papaver somniferum L., except
784	784	384
785	785	the seeds of the plant.
786	786	385
787	787	[(gg)] (ii) "Person" means any corporation, association, partnership, trust, other
788	788	386
789	789	institution or entity or one or more individuals.
790	790	387
791	791	[(hh)] (jj) "Poppy straw" means all parts, except the seeds, of the opium poppy, after
792	792	388
793	793	mowing.
794	794	389
795	795	[(ii)] (kk) "Possession" or "use" means the joint or individual ownership, control,
796	796	390
797	797	occupancy, holding, retaining, belonging, maintaining, or the application, inhalation,
798	798	391
799	799	swallowing, injection, or consumption, as distinguished from distribution, of
800	800	392
801	801	controlled substances and includes individual, joint, or group possession or use of
802	802	393
803	803	controlled substances. For a person to be a possessor or user of a controlled
804	804	394
805	805	substance, it is not required that the person be shown to have individually possessed,
806	806	395
807	807	used, or controlled the substance, but it is sufficient if it is shown that the person
808	808	396
809	809	jointly participated with one or more persons in the use, possession, or control of any
810	810	397
811	811	substances with knowledge that the activity was occurring, or the controlled
812	812	398
813	813	substance is found in a place or under circumstances indicating that the person had
814	814	399
815	815	the ability and the intent to exercise dominion and control over it.
816	816	400
817	817	[(jj)] (ll) "Practitioner" means a physician, dentist, naturopathic physician, veterinarian,
818	818	401
819	819	pharmacist, scientific investigator, pharmacy, hospital, or other person [licensed,
820	820	402
821	821	registered, or otherwise permitted to distribute, dispense, conduct research with
822	822	403
823	823	respect to, administer, or use in teaching or chemical analysis a controlled substance
824	824	404
825	825	in the course of professional practice or research in this state] with a controlled
826	826	- 12 - 02-21 16:04 H.B. 543
827	827	405
828	828	substance certification.
829	829	406
830	830	[(kk)] (mm) "Prescribe" means to issue a prescription:
831	831	407
832	832	(i) orally or in writing; or
833	833	408
834	834	(ii) by telephone, facsimile transmission, computer, or other electronic means of
835	835	409
836	836	communication as defined by division rule.
837	837	410
838	838	[(ll)] (nn) "Prescription" means an order issued:
839	839	411
840	840	(i) by a [licensed] certified practitioner, in the course of that practitioner's professional
841	841	412
842	842	practice or by collaborative pharmacy practice agreement; and
843	843	413
844	844	(ii) for a controlled substance or other prescription drug or device for use by a patient
845	845	414
846	846	or an animal.
847	847	415
848	848	[(mm)] (oo) "Production" means the manufacture, planting, cultivation, growing, or
849	849	416
850	850	harvesting of a controlled substance.
851	851	417
852	852	[(nn)] (pp) "Securities" means any stocks, bonds, notes, or other evidences of debt or of
853	853	418
854	854	property.
855	855	419
856	856	[(oo) "State" means the state of Utah.]
857	857	420
858	858	[(pp)] (qq) "Ultimate user" means any person who lawfully possesses a controlled
859	859	421
860	860	substance for the person's own use, for the use of a member of the person's
861	861	422
862	862	household, or for administration to an animal owned by the person or a member of
863	863	423
864	864	the person's household.
865	865	424
866	866	(2) If a term used in this chapter is not defined, the definition and terms of Title 76, Utah
867	867	425
868	868	Criminal Code, shall apply.
869	869	426
870	870	Section 4. Section 58-37-4 is amended to read:
871	871	427
872	872	58-37-4 (Effective 07/01/25). Schedules of controlled substances -- Schedules I
873	873	428
874	874	through V -- Findings required -- Specific substances included in schedules.
875	875	429
876	876	(1) There are established five schedules of controlled substances known as Schedules I, II,
877	877	430
878	878	III, IV, and V which consist of substances listed in this section.
879	879	431
880	880	(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the
881	881	432
882	882	official name, common or usual name, chemical name, or brand name designated:
883	883	433
884	884	(a) Schedule I:
885	885	434
886	886	(i) Unless specifically excepted or unless listed in another schedule, any of the
887	887	435
888	888	following opiates, including their isomers, esters, ethers, salts, and salts of
889	889	436
890	890	isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
891	891	437
892	892	salts is possible within the specific chemical designation:
893	893	438
894	894	(A) Acetyl-alpha-methylfentanyl
895	895	- 13 - H.B. 543 02-21 16:04
896	896	439
897	897	(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
898	898	440
899	899	(B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
900	900	441
901	901	(C) Acetylmethadol;
902	902	442
903	903	(D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
904	904	443
905	905	(E) Allylprodine;
906	906	444
907	907	(F) Alphacetylmethadol, except levo-alphacetylmethadol also known as
908	908	445
909	909	levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
910	910	446
911	911	(G) Alphameprodine;
912	912	447
913	913	(H) Alphamethadol;
914	914	448
915	915	(I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
916	916	449
917	917	propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
918	918	450
919	919	(J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
920	920	451
921	921	piperidinyl]-N-phenylpropanamide);
922	922	452
923	923	(K) Benzylpiperazine;
924	924	453
925	925	(L) Benzethidine;
926	926	454
927	927	(M) Betacetylmethadol;
928	928	455
929	929	(N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
930	930	456
931	931	piperidinyl]-N-phenylpropanamide);
932	932	457
933	933	(O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
934	934	458
935	935	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
936	936	459
937	937	(P) Betameprodine;
938	938	460
939	939	(Q) Betamethadol;
940	940	461
941	941	(R) Betaprodine;
942	942	462
943	943	(S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
944	944	463
945	945	(T) Clonitazene;
946	946	464
947	947	(U) Cyclopropyl fentanyl
948	948	465
949	949	(N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
950	950	466
951	951	(V) Dextromoramide;
952	952	467
953	953	(W) Diampromide;
954	954	468
955	955	(X) Diethylthiambutene;
956	956	469
957	957	(Y) Difenoxin;
958	958	470
959	959	(Z) Dimenoxadol;
960	960	471
961	961	(AA) Dimepheptanol;
962	962	472
963	963	(BB) Dimethylthiambutene;
964	964	- 14 - 02-21 16:04 H.B. 543
965	965	473
966	966	(CC) Dioxaphetyl butyrate;
967	967	474
968	968	(DD) Dipipanone;
969	969	475
970	970	(EE) Ethylmethylthiambutene;
971	971	476
972	972	(FF) Etizolam
973	973	477
974	974	(1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
975	975	478
976	976	(GG) Etonitazene;
977	977	479
978	978	(HH) Etoxeridine;
979	979	480
980	980	(II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
981	981	481
982	982	furan-2-carboxamide);
983	983	482
984	984	(JJ) Furethidine;
985	985	483
986	986	(KK) Hydroxypethidine;
987	987	484
988	988	(LL) Ketobemidone;
989	989	485
990	990	(MM) Levomoramide;
991	991	486
992	992	(NN) Levophenacylmorphan;
993	993	487
994	994	(OO) Methoxyacetyl fentanyl
995	995	488
996	996	(2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
997	997	489
998	998	(PP) Morpheridine;
999	999	490
1000	1000	(QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
1001	1001	491
1002	1002	(RR) Noracymethadol;
1003	1003	492
1004	1004	(SS) Norlevorphanol;
1005	1005	493
1006	1006	(TT) Normethadone;
1007	1007	494
1008	1008	(UU) Norpipanone;
1009	1009	495
1010	1010	(VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
1011	1011	496
1012	1012	propanamide);
1013	1013	497
1014	1014	(WW) Para-fluoroisobutyryl fentanyl
1015	1015	498
1016	1016	(N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
1017	1017	499
1018	1018	(XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
1019	1019	500
1020	1020	(YY) Phenadoxone;
1021	1021	501
1022	1022	(ZZ) Phenampromide;
1023	1023	502
1024	1024	(AAA) Phenomorphan;
1025	1025	503
1026	1026	(BBB) Phenoperidine;
1027	1027	504
1028	1028	(CCC) Piritramide;
1029	1029	505
1030	1030	(DDD) Proheptazine;
1031	1031	506
1032	1032	(EEE) Properidine;
1033	1033	- 15 - H.B. 543 02-21 16:04
1034	1034	507
1035	1035	(FFF) Propiram;
1036	1036	508
1037	1037	(GGG) Racemoramide;
1038	1038	509
1039	1039	(HHH) Tetrahydrofuran fentanyl
1040	1040	510
1041	1041	(N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
1042	1042	511
1043	1043	(III) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
1044	1044	512
1045	1045	(JJJ) Tilidine;
1046	1046	513
1047	1047	(KKK) Trimeperidine;
1048	1048	514
1049	1049	(LLL) 3-methylfentanyl, including the optical and geometric isomers
1050	1050	515
1051	1051	(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
1052	1052	516
1053	1053	(MMM) 3-methylthiofentanyl
1054	1054	517
1055	1055	(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
1056	1056	518
1057	1057	(NNN) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also
1058	1058	519
1059	1059	known as U-47700; and
1060	1060	520
1061	1061	(OOO) 4-cyano CUMYL-BUTINACA.
1062	1062	521
1063	1063	(ii) Unless specifically excepted or unless listed in another schedule, any of the
1064	1064	522
1065	1065	following opium derivatives, their salts, isomers, and salts of isomers when the
1066	1066	523
1067	1067	existence of the salts, isomers, and salts of isomers is possible within the specific
1068	1068	524
1069	1069	chemical designation:
1070	1070	525
1071	1071	(A) Acetorphine;
1072	1072	526
1073	1073	(B) Acetyldihydrocodeine;
1074	1074	527
1075	1075	(C) Benzylmorphine;
1076	1076	528
1077	1077	(D) Codeine methylbromide;
1078	1078	529
1079	1079	(E) Codeine-N-Oxide;
1080	1080	530
1081	1081	(F) Cyprenorphine;
1082	1082	531
1083	1083	(G) Desomorphine;
1084	1084	532
1085	1085	(H) Dihydromorphine;
1086	1086	533
1087	1087	(I) Drotebanol;
1088	1088	534
1089	1089	(J) Etorphine (except hydrochloride salt);
1090	1090	535
1091	1091	(K) Heroin;
1092	1092	536
1093	1093	(L) Hydromorphinol;
1094	1094	537
1095	1095	(M) Methyldesorphine;
1096	1096	538
1097	1097	(N) Methylhydromorphine;
1098	1098	539
1099	1099	(O) Morphine methylbromide;
1100	1100	540
1101	1101	(P) Morphine methylsulfonate;
1102	1102	- 16 - 02-21 16:04 H.B. 543
1103	1103	541
1104	1104	(Q) Morphine-N-Oxide;
1105	1105	542
1106	1106	(R) Myrophine;
1107	1107	543
1108	1108	(S) Nicocodeine;
1109	1109	544
1110	1110	(T) Nicomorphine;
1111	1111	545
1112	1112	(U) Normorphine;
1113	1113	546
1114	1114	(V) Pholcodine; and
1115	1115	547
1116	1116	(W) Thebacon.
1117	1117	548
1118	1118	(iii) Unless specifically excepted or unless listed in another schedule, any material,
1119	1119	549
1120	1120	compound, mixture, or preparation which contains any quantity of the following
1121	1121	550
1122	1122	hallucinogenic substances, or which contains any of their salts, isomers, and salts
1123	1123	551
1124	1124	of isomers when the existence of the salts, isomers, and salts of isomers is possible
1125	1125	552
1126	1126	within the specific chemical designation; as used in this Subsection (2)(a)(iii)
1127	1127	553
1128	1128	only, "isomer" includes the optical, position, and geometric isomers:
1129	1129	554
1130	1130	(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α
1131	1131	555
1132	1132	-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α-ET; and AET;
1133	1133	556
1134	1134	(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
1135	1135	557
1136	1136	4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
1137	1137	558
1138	1138	(C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
1139	1139	559
1140	1140	2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;
1141	1141	560
1142	1142	2C-B, Nexus;
1143	1143	561
1144	1144	(D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-α
1145	1145	562
1146	1146	-methylphenethylamine; 2,5-DMA;
1147	1147	563
1148	1148	(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
1149	1149	564
1150	1150	(F) 4-methoxyamphetamine, some trade or other names: 4-methoxy-α
1151	1151	565
1152	1152	-methylphenethylamine; paramethoxyamphetamine, PMA;
1153	1153	566
1154	1154	(G) 5-methoxy-3,4-methylenedioxyamphetamine;
1155	1155	567
1156	1156	(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
1157	1157	568
1158	1158	4-methyl-2,5-dimethoxy-α-methylphenethylamine; "DOM"; and "STP";
1159	1159	569
1160	1160	(I) 3,4-methylenedioxy amphetamine;
1161	1161	570
1162	1162	(J) 3,4-methylenedioxymethamphetamine (MDMA);
1163	1163	571
1164	1164	(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
1165	1165	572
1166	1166	alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE,
1167	1167	573
1168	1168	MDEA;
1169	1169	574
1170	1170	(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
1171	1171	- 17 - H.B. 543 02-21 16:04
1172	1172	575
1173	1173	N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy
1174	1174	576
1175	1175	MDA;
1176	1176	577
1177	1177	(M) 3,4,5-trimethoxy amphetamine;
1178	1178	578
1179	1179	(N) Bufotenine, some trade and other names: 3-(β
1180	1180	579
1181	1181	-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol;
1182	1182	580
1183	1183	N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
1184	1184	581
1185	1185	(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
1186	1186	582
1187	1187	(P) Dimethyltryptamine, some trade or other names: DMT;
1188	1188	583
1189	1189	(Q) Ibogaine, some trade and other names: 7-Ethyl-6,6β
1190	1190	584
1191	1191	,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]
1192	1192	585
1193	1193	azepino [5,4-b] indole; Tabernanthe iboga;
1194	1194	586
1195	1195	(R) Lysergic acid diethylamide;
1196	1196	587
1197	1197	(S) Marijuana;
1198	1198	588
1199	1199	(T) Mescaline;
1200	1200	589
1201	1201	(U) Parahexyl, some trade or other names:
1202	1202	590
1203	1203	3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
1204	1204	591
1205	1205	Synhexyl;
1206	1206	592
1207	1207	(V) Peyote, meaning all parts of the plant presently classified botanically as
1208	1208	593
1209	1209	Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any
1210	1210	594
1211	1211	extract from any part of such plant, and every compound, manufacture, salts,
1212	1212	595
1213	1213	derivative, mixture, or preparation of such plant, its seeds or extracts
1214	1214	596
1215	1215	(Interprets 21 USC 812(c), Schedule I(c) (12));
1216	1216	597
1217	1217	(W) N-ethyl-3-piperidyl benzilate;
1218	1218	598
1219	1219	(X) N-methyl-3-piperidyl benzilate;
1220	1220	599
1221	1221	(Y) Psilocybin;
1222	1222	600
1223	1223	(Z) Psilocyn;
1224	1224	601
1225	1225	(AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
1226	1226	602
1227	1227	(cannabis plant), except for marijuana as defined in Subsection [58-37-2
1228	1228	603
1229	1229	(1)(aa)(i)(E)] 58-37-2(1)(cc)(i)(E), as well as synthetic equivalents of the
1230	1230	604
1231	1231	substances contained in the cannabis plant, or in the resinous extractives of
1232	1232	605
1233	1233	Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with
1234	1234	606
1235	1235	similar chemical structure and pharmacological activity to those substances
1236	1236	607
1237	1237	contained in the plant, such as the following: Δ1 cis or trans
1238	1238	608
1239	1239	tetrahydrocannabinol, and their optical isomers Δ6 cis or trans
1240	1240	- 18 - 02-21 16:04 H.B. 543
1241	1241	609
1242	1242	tetrahydrocannabinol, and their optical isomers Δ3,4 cis or trans
1243	1243	610
1244	1244	tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
1245	1245	611
1246	1246	substances is not internationally standardized, compounds of these structures,
1247	1247	612
1248	1248	regardless of numerical designation of atomic positions covered;
1249	1249	613
1250	1250	(BB) Ethylamine analog of phencyclidine, some trade or other names:
1251	1251	614
1252	1252	N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
1253	1253	615
1254	1254	N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
1255	1255	616
1256	1256	(CC) Pyrrolidine analog of phencyclidine, some trade or other names:
1257	1257	617
1258	1258	1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
1259	1259	618
1260	1260	(DD) Thiophene analog of phencyclidine, some trade or other names:
1261	1261	619
1262	1262	1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine,
1263	1263	620
1264	1264	TPCP, TCP; and
1265	1265	621
1266	1266	(EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
1267	1267	622
1268	1268	(iv) Unless specifically excepted or unless listed in another schedule, any material
1269	1269	623
1270	1270	compound, mixture, or preparation which contains any quantity of the following
1271	1271	624
1272	1272	substances having a depressant effect on the central nervous system, including its
1273	1273	625
1274	1274	salts, isomers, and salts of isomers when the existence of the salts, isomers, and
1275	1275	626
1276	1276	salts of isomers is possible within the specific chemical designation:
1277	1277	627
1278	1278	(A) Mecloqualone; and
1279	1279	628
1280	1280	(B) Methaqualone.
1281	1281	629
1282	1282	(v) Any material, compound, mixture, or preparation containing any quantity of the
1283	1283	630
1284	1284	following substances having a stimulant effect on the central nervous system,
1285	1285	631
1286	1286	including their salts, isomers, and salts of isomers:
1287	1287	632
1288	1288	(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
1289	1289	633
1290	1290	or 4,5-dihydro-5-phenyl-2-oxazolamine;
1291	1291	634
1292	1292	(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
1293	1293	635
1294	1294	alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
1295	1295	636
1296	1296	(C) Fenethylline;
1297	1297	637
1298	1298	(D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
1299	1299	638
1300	1300	alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
1301	1301	639
1302	1302	alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone;
1303	1303	640
1304	1304	N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432,
1305	1305	641
1306	1306	its salts, optical isomers, and salts of optical isomers;
1307	1307	642
1308	1308	(E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
1309	1309	- 19 - H.B. 543 02-21 16:04
1310	1310	643
1311	1311	(F) N-ethylamphetamine; and
1312	1312	644
1313	1313	(G) N,N-dimethylamphetamine, also known as
1314	1314	645
1315	1315	N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
1316	1316	646
1317	1317	(vi) Any material, compound, mixture, or preparation which contains any quantity of
1318	1318	647
1319	1319	the following substances, including their optical isomers, salts, and salts of
1320	1320	648
1321	1321	isomers, subject to temporary emergency scheduling:
1322	1322	649
1323	1323	(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
1324	1324	650
1325	1325	(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
1326	1326	651
1327	1327	(vii) Unless specifically excepted or unless listed in another schedule, any material,
1328	1328	652
1329	1329	compound, mixture, or preparation which contains any quantity of gamma
1330	1330	653
1331	1331	hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and
1332	1332	654
1333	1333	salts of isomers.
1334	1334	655
1335	1335	(b) Schedule II:
1336	1336	656
1337	1337	(i) Unless specifically excepted or unless listed in another schedule, any of the
1338	1338	657
1339	1339	following substances whether produced directly or indirectly by extraction from
1340	1340	658
1341	1341	substances of vegetable origin, or independently by means of chemical synthesis,
1342	1342	659
1343	1343	or by a combination of extraction and chemical synthesis:
1344	1344	660
1345	1345	(A) Opium and opiate, and any salt, compound, derivative, or preparation of
1346	1346	661
1347	1347	opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene,
1348	1348	662
1349	1349	naloxone, and naltrexone, and their respective salts, but including:
1350	1350	663
1351	1351	(I) Raw opium;
1352	1352	664
1353	1353	(II) Opium extracts;
1354	1354	665
1355	1355	(III) Opium fluid;
1356	1356	666
1357	1357	(IV) Powdered opium;
1358	1358	667
1359	1359	(V) Granulated opium;
1360	1360	668
1361	1361	(VI) Tincture of opium;
1362	1362	669
1363	1363	(VII) Codeine;
1364	1364	670
1365	1365	(VIII) Ethylmorphine;
1366	1366	671
1367	1367	(IX) Etorphine hydrochloride;
1368	1368	672
1369	1369	(X) Hydrocodone;
1370	1370	673
1371	1371	(XI) Hydromorphone;
1372	1372	674
1373	1373	(XII) Metopon;
1374	1374	675
1375	1375	(XIII) Morphine;
1376	1376	676
1377	1377	(XIV) Oxycodone;
1378	1378	- 20 - 02-21 16:04 H.B. 543
1379	1379	677
1380	1380	(XV) Oxymorphone; and
1381	1381	678
1382	1382	(XVI) Thebaine;
1383	1383	679
1384	1384	(B) Any salt, compound, derivative, or preparation which is chemically equivalent
1385	1385	680
1386	1386	or identical with any of the substances referred to in Subsection (2)(b)(i)(A),
1387	1387	681
1388	1388	except that these substances may not include the isoquinoline alkaloids of
1389	1389	682
1390	1390	opium;
1391	1391	683
1392	1392	(C) Opium poppy and poppy straw;
1393	1393	684
1394	1394	(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves,
1395	1395	685
1396	1396	and any salt, compound, derivative, or preparation which is chemically
1397	1397	686
1398	1398	equivalent or identical with any of these substances, and includes cocaine and
1399	1399	687
1400	1400	ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,
1401	1401	688
1402	1402	whether derived from the coca plant or synthetically produced, except the
1403	1403	689
1404	1404	substances may not include decocainized coca leaves or extraction of coca
1405	1405	690
1406	1406	leaves, which extractions do not contain cocaine or ecgonine; and
1407	1407	691
1408	1408	(E) Concentrate of poppy straw, which means the crude extract of poppy straw in
1409	1409	692
1410	1410	either liquid, solid, or powder form which contains the phenanthrene alkaloids
1411	1411	693
1412	1412	of the opium poppy.
1413	1413	694
1414	1414	(ii) Unless specifically excepted or unless listed in another schedule, any of the
1415	1415	695
1416	1416	following opiates, including their isomers, esters, ethers, salts, and salts of
1417	1417	696
1418	1418	isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
1419	1419	697
1420	1420	salts is possible within the specific chemical designation, except dextrorphan and
1421	1421	698
1422	1422	levopropoxyphene:
1423	1423	699
1424	1424	(A) Alfentanil;
1425	1425	700
1426	1426	(B) Alphaprodine;
1427	1427	701
1428	1428	(C) Anileridine;
1429	1429	702
1430	1430	(D) Bezitramide;
1431	1431	703
1432	1432	(E) Bulk dextropropoxyphene (nondosage forms);
1433	1433	704
1434	1434	(F) Carfentanil;
1435	1435	705
1436	1436	(G) Dihydrocodeine;
1437	1437	706
1438	1438	(H) Diphenoxylate;
1439	1439	707
1440	1440	(I) Fentanyl;
1441	1441	708
1442	1442	(J) Isomethadone;
1443	1443	709
1444	1444	(K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
1445	1445	710
1446	1446	levomethadyl acetate, or LAAM;
1447	1447	- 21 - H.B. 543 02-21 16:04
1448	1448	711
1449	1449	(L) Levomethorphan;
1450	1450	712
1451	1451	(M) Levorphanol;
1452	1452	713
1453	1453	(N) Metazocine;
1454	1454	714
1455	1455	(O) Methadone;
1456	1456	715
1457	1457	(P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
1458	1458	716
1459	1459	(Q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
1460	1460	717
1461	1461	1-diphenylpropane-carboxylic acid;
1462	1462	718
1463	1463	(R) Pethidine (meperidine);
1464	1464	719
1465	1465	(S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
1466	1466	720
1467	1467	(T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
1468	1468	721
1469	1469	(U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
1470	1470	722
1471	1471	(V) Phenazocine;
1472	1472	723
1473	1473	(W) Piminodine;
1474	1474	724
1475	1475	(X) Racemethorphan;
1476	1476	725
1477	1477	(Y) Racemorphan;
1478	1478	726
1479	1479	(Z) Remifentanil; and
1480	1480	727
1481	1481	(AA) Sufentanil.
1482	1482	728
1483	1483	(iii) Unless specifically excepted or unless listed in another schedule, any material,
1484	1484	729
1485	1485	compound, mixture, or preparation which contains any quantity of the following
1486	1486	730
1487	1487	substances having a stimulant effect on the central nervous system:
1488	1488	731
1489	1489	(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
1490	1490	732
1491	1491	(B) Methamphetamine, its salts, isomers, and salts of its isomers;
1492	1492	733
1493	1493	(C) Phenmetrazine and its salts; and
1494	1494	734
1495	1495	(D) Methylphenidate.
1496	1496	735
1497	1497	(iv) Unless specifically excepted or unless listed in another schedule, any material,
1498	1498	736
1499	1499	compound, mixture, or preparation which contains any quantity of the following
1500	1500	737
1501	1501	substances having a depressant effect on the central nervous system, including its
1502	1502	738
1503	1503	salts, isomers, and salts of isomers when the existence of the salts, isomers, and
1504	1504	739
1505	1505	salts of isomers is possible within the specific chemical designation:
1506	1506	740
1507	1507	(A) Amobarbital;
1508	1508	741
1509	1509	(B) Glutethimide;
1510	1510	742
1511	1511	(C) Pentobarbital;
1512	1512	743
1513	1513	(D) Phencyclidine;
1514	1514	744
1515	1515	(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
1516	1516	- 22 - 02-21 16:04 H.B. 543
1517	1517	745
1518	1518	1-piperidinocyclohexanecarbonitrile (PCC); and
1519	1519	746
1520	1520	(F) Secobarbital.
1521	1521	747
1522	1522	(v)(A) Unless specifically excepted or unless listed in another schedule, any
1523	1523	748
1524	1524	material, compound, mixture, or preparation which contains any quantity of
1525	1525	749
1526	1526	Phenylacetone.
1527	1527	750
1528	1528	(B) Some of these substances may be known by trade or other names:
1529	1529	751
1530	1530	phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
1531	1531	752
1532	1532	(vi) Nabilone, another name for nabilone: (±
1533	1533	753
1534	1534	)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
1535	1535	754
1536	1536	6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
1537	1537	755
1538	1538	(vii) A drug product or preparation that contains any component of marijuana,
1539	1539	756
1540	1540	including tetrahydrocannabinol, and is approved by the United States Food and
1541	1541	757
1542	1542	Drug Administration and scheduled by the federal Drug Enforcement
1543	1543	758
1544	1544	Administration in Schedule II of the federal Controlled Substances Act, Title II,
1545	1545	759
1546	1546	P.L. 91-513.
1547	1547	760
1548	1548	(c) Schedule III:
1549	1549	761
1550	1550	(i) Unless specifically excepted or unless listed in another schedule, any material,
1551	1551	762
1552	1552	compound, mixture, or preparation which contains any quantity of the following
1553	1553	763
1554	1554	substances having a stimulant effect on the central nervous system, including its
1555	1555	764
1556	1556	salts, isomers whether optical, position, or geometric, and salts of the isomers
1557	1557	765
1558	1558	when the existence of the salts, isomers, and salts of isomers is possible within the
1559	1559	766
1560	1560	specific chemical designation:
1561	1561	767
1562	1562	(A) Those compounds, mixtures, or preparations in dosage unit form containing
1563	1563	768
1564	1564	any stimulant substances listed in Schedule II, which compounds, mixtures, or
1565	1565	769
1566	1566	preparations were listed on August 25, 1971, as excepted compounds under
1567	1567	770
1568	1568	Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other
1569	1569	771
1570	1570	drug of the quantitive composition shown in that list for those drugs or which
1571	1571	772
1572	1572	is the same except that it contains a lesser quantity of controlled substances;
1573	1573	773
1574	1574	(B) Benzphetamine;
1575	1575	774
1576	1576	(C) Chlorphentermine;
1577	1577	775
1578	1578	(D) Clortermine; and
1579	1579	776
1580	1580	(E) Phendimetrazine.
1581	1581	777
1582	1582	(ii) Unless specifically excepted or unless listed in another schedule, any material,
1583	1583	778
1584	1584	compound, mixture, or preparation which contains any quantity of the following
1585	1585	- 23 - H.B. 543 02-21 16:04
1586	1586	779
1587	1587	substances having a depressant effect on the central nervous system:
1588	1588	780
1589	1589	(A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
1590	1590	781
1591	1591	pentobarbital, or any salt of any of them, and one or more other active
1592	1592	782
1593	1593	medicinal ingredients which are not listed in any schedule;
1594	1594	783
1595	1595	(B) Any suppository dosage form containing amobarbital, secobarbital, or
1596	1596	784
1597	1597	pentobarbital, or any salt of any of these drugs which is approved by the United
1598	1598	785
1599	1599	States Food and Drug Administration for marketing only as a suppository;
1600	1600	786
1601	1601	(C) Any substance which contains any quantity of a derivative of barbituric acid
1602	1602	787
1603	1603	or any salt of any of them;
1604	1604	788
1605	1605	(D) Chlorhexadol;
1606	1606	789
1607	1607	(E) Buprenorphine;
1608	1608	790
1609	1609	(F) Any drug product containing gamma hydroxybutyric acid, including its salts,
1610	1610	791
1611	1611	isomers, and salts of isomers, for which an application is approved under the
1612	1612	792
1613	1613	federal Food, Drug, and Cosmetic Act, Section 505;
1614	1614	793
1615	1615	(G) Ketamine, its salts, isomers, and salts of isomers, some other names for
1616	1616	794
1617	1617	ketamine: ± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
1618	1618	795
1619	1619	(H) Lysergic acid;
1620	1620	796
1621	1621	(I) Lysergic acid amide;
1622	1622	797
1623	1623	(J) Methyprylon;
1624	1624	798
1625	1625	(K) Sulfondiethylmethane;
1626	1626	799
1627	1627	(L) Sulfonethylmethane;
1628	1628	800
1629	1629	(M) Sulfonmethane; and
1630	1630	801
1631	1631	(N) Tiletamine and zolazepam or any of their salts, some trade or other names for
1632	1632	802
1633	1633	a tiletamine-zolazepam combination product: Telazol, some trade or other
1634	1634	803
1635	1635	names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade
1636	1636	804
1637	1637	or other names for zolazepam:
1638	1638	805
1639	1639	4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
1640	1640	806
1641	1641	[1,4]-diazepin-7(1H)-one, flupyrazapon.
1642	1642	807
1643	1643	(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
1644	1644	808
1645	1645	a U.S. Food and Drug Administration approved drug product, some other names
1646	1646	809
1647	1647	for dronabinol:
1648	1648	810
1649	1649	(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,
1650	1650	811
1651	1651	or (-)-delta-9-(trans)-tetrahydrocannabinol.
1652	1652	812
1653	1653	(iv) Nalorphine.
1654	1654	- 24 - 02-21 16:04 H.B. 543
1655	1655	813
1656	1656	(v) Unless specifically excepted or unless listed in another schedule, any material,
1657	1657	814
1658	1658	compound, mixture, or preparation containing limited quantities of any of the
1659	1659	815
1660	1660	following narcotic drugs, or their salts calculated as the free anhydrous base or
1661	1661	816
1662	1662	alkaloid:
1663	1663	817
1664	1664	(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
1665	1665	818
1666	1666	milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
1667	1667	819
1668	1668	alkaloid of opium;
1669	1669	820
1670	1670	(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
1671	1671	821
1672	1672	milligrams per dosage unit, with one or more active non-narcotic ingredients in
1673	1673	822
1674	1674	recognized therapeutic amounts;
1675	1675	823
1676	1676	(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
1677	1677	824
1678	1678	more than 15 milligrams per dosage unit, with a fourfold or greater quantity of
1679	1679	825
1680	1680	an isoquinoline alkaloid of opium;
1681	1681	826
1682	1682	(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
1683	1683	827
1684	1684	more than 15 milligrams per dosage unit, with one or more active, non-narcotic
1685	1685	828
1686	1686	ingredients in recognized therapeutic amounts;
1687	1687	829
1688	1688	(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
1689	1689	830
1690	1690	than 90 milligrams per dosage unit, with one or more active non-narcotic
1691	1691	831
1692	1692	ingredients in recognized therapeutic amounts;
1693	1693	832
1694	1694	(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
1695	1695	833
1696	1696	than 15 milligrams per dosage unit, with one or more active, non-narcotic
1697	1697	834
1698	1698	ingredients in recognized therapeutic amounts;
1699	1699	835
1700	1700	(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
1701	1701	836
1702	1702	or not more than 25 milligrams per dosage unit, with one or more active,
1703	1703	837
1704	1704	non-narcotic ingredients in recognized therapeutic amounts; and
1705	1705	838
1706	1706	(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
1707	1707	839
1708	1708	with one or more active, non-narcotic ingredients in recognized therapeutic
1709	1709	840
1710	1710	amounts.
1711	1711	841
1712	1712	(vi) Unless specifically excepted or unless listed in another schedule, anabolic
1713	1713	842
1714	1714	steroids including any of the following or any isomer, ester, salt, or derivative of
1715	1715	843
1716	1716	the following that promotes muscle growth:
1717	1717	844
1718	1718	(A) Boldenone;
1719	1719	845
1720	1720	(B) Chlorotestosterone (4-chlortestosterone);
1721	1721	846
1722	1722	(C) Clostebol;
1723	1723	- 25 - H.B. 543 02-21 16:04
1724	1724	847
1725	1725	(D) Dehydrochlormethyltestosterone;
1726	1726	848
1727	1727	(E) Dihydrotestosterone (4-dihydrotestosterone);
1728	1728	849
1729	1729	(F) Drostanolone;
1730	1730	850
1731	1731	(G) Ethylestrenol;
1732	1732	851
1733	1733	(H) Fluoxymesterone;
1734	1734	852
1735	1735	(I) Formebulone (formebolone);
1736	1736	853
1737	1737	(J) Mesterolone;
1738	1738	854
1739	1739	(K) Methandienone;
1740	1740	855
1741	1741	(L) Methandranone;
1742	1742	856
1743	1743	(M) Methandriol;
1744	1744	857
1745	1745	(N) Methandrostenolone;
1746	1746	858
1747	1747	(O) Methenolone;
1748	1748	859
1749	1749	(P) Methyltestosterone;
1750	1750	860
1751	1751	(Q) Mibolerone;
1752	1752	861
1753	1753	(R) Nandrolone;
1754	1754	862
1755	1755	(S) Norethandrolone;
1756	1756	863
1757	1757	(T) Oxandrolone;
1758	1758	864
1759	1759	(U) Oxymesterone;
1760	1760	865
1761	1761	(V) Oxymetholone;
1762	1762	866
1763	1763	(W) Stanolone;
1764	1764	867
1765	1765	(X) Stanozolol;
1766	1766	868
1767	1767	(Y) Testolactone;
1768	1768	869
1769	1769	(Z) Testosterone; and
1770	1770	870
1771	1771	(AA) Trenbolone.
1772	1772	871
1773	1773	(vii) Anabolic steroids expressly intended for administration through implants to
1774	1774	872
1775	1775	cattle or other nonhuman species, and approved by the Secretary of Health and
1776	1776	873
1777	1777	Human Services for use, may not be classified as a controlled substance.
1778	1778	874
1779	1779	(viii) A drug product or preparation that contains any component of marijuana,
1780	1780	875
1781	1781	including tetrahydrocannabinol, and is approved by the United States Food and
1782	1782	876
1783	1783	Drug Administration and scheduled by the federal Drug Enforcement
1784	1784	877
1785	1785	Administration in Schedule III of the federal Controlled Substances Act, Title II,
1786	1786	878
1787	1787	P.L. 91-513.
1788	1788	879
1789	1789	(ix) Nabiximols.
1790	1790	880
1791	1791	(d) Schedule IV:
1792	1792	- 26 - 02-21 16:04 H.B. 543
1793	1793	881
1794	1794	(i) Unless specifically excepted or unless listed in another schedule, any material,
1795	1795	882
1796	1796	compound, mixture, or preparation containing not more than 1 milligram of
1797	1797	883
1798	1798	difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or
1799	1799	884
1800	1800	any salts of any of them.
1801	1801	885
1802	1802	(ii) Unless specifically excepted or unless listed in another schedule, any material,
1803	1803	886
1804	1804	compound, mixture, or preparation which contains any quantity of the following
1805	1805	887
1806	1806	substances, including its salts, isomers, and salts of isomers when the existence of
1807	1807	888
1808	1808	the salts, isomers, and salts of isomers is possible within the specific chemical
1809	1809	889
1810	1810	designation:
1811	1811	890
1812	1812	(A) Alprazolam;
1813	1813	891
1814	1814	(B) Barbital;
1815	1815	892
1816	1816	(C) Bromazepam;
1817	1817	893
1818	1818	(D) Butorphanol;
1819	1819	894
1820	1820	(E) Camazepam;
1821	1821	895
1822	1822	(F) Carisoprodol;
1823	1823	896
1824	1824	(G) Chloral betaine;
1825	1825	897
1826	1826	(H) Chloral hydrate;
1827	1827	898
1828	1828	(I) Chlordiazepoxide;
1829	1829	899
1830	1830	(J) Clobazam;
1831	1831	900
1832	1832	(K) Clonazepam;
1833	1833	901
1834	1834	(L) Clorazepate;
1835	1835	902
1836	1836	(M) Clotiazepam;
1837	1837	903
1838	1838	(N) Cloxazolam;
1839	1839	904
1840	1840	(O) Delorazepam;
1841	1841	905
1842	1842	(P) Diazepam;
1843	1843	906
1844	1844	(Q) Dichloralphenazone;
1845	1845	907
1846	1846	(R) Estazolam;
1847	1847	908
1848	1848	(S) Ethchlorvynol;
1849	1849	909
1850	1850	(T) Ethinamate;
1851	1851	910
1852	1852	(U) Ethyl loflazepate;
1853	1853	911
1854	1854	(V) Fludiazepam;
1855	1855	912
1856	1856	(W) Flunitrazepam;
1857	1857	913
1858	1858	(X) Flurazepam;
1859	1859	914
1860	1860	(Y) Halazepam;
1861	1861	- 27 - H.B. 543 02-21 16:04
1862	1862	915
1863	1863	(Z) Haloxazolam;
1864	1864	916
1865	1865	(AA) Ketazolam;
1866	1866	917
1867	1867	(BB) Loprazolam;
1868	1868	918
1869	1869	(CC) Lorazepam;
1870	1870	919
1871	1871	(DD) Lormetazepam;
1872	1872	920
1873	1873	(EE) Mebutamate;
1874	1874	921
1875	1875	(FF) Medazepam;
1876	1876	922
1877	1877	(GG) Meprobamate;
1878	1878	923
1879	1879	(HH) Methohexital;
1880	1880	924
1881	1881	(II) Methylphenobarbital (mephobarbital);
1882	1882	925
1883	1883	(JJ) Midazolam;
1884	1884	926
1885	1885	(KK) Nimetazepam;
1886	1886	927
1887	1887	(LL) Nitrazepam;
1888	1888	928
1889	1889	(MM) Nordiazepam;
1890	1890	929
1891	1891	(NN) Oxazepam;
1892	1892	930
1893	1893	(OO) Oxazolam;
1894	1894	931
1895	1895	(PP) Paraldehyde;
1896	1896	932
1897	1897	(QQ) Pentazocine;
1898	1898	933
1899	1899	(RR) Petrichloral;
1900	1900	934
1901	1901	(SS) Phenobarbital;
1902	1902	935
1903	1903	(TT) Pinazepam;
1904	1904	936
1905	1905	(UU) Prazepam;
1906	1906	937
1907	1907	(VV) Quazepam;
1908	1908	938
1909	1909	(WW) Temazepam;
1910	1910	939
1911	1911	(XX) Tetrazepam;
1912	1912	940
1913	1913	(YY) Tramadol;
1914	1914	941
1915	1915	(ZZ) Triazolam;
1916	1916	942
1917	1917	(AAA) Zaleplon; and
1918	1918	943
1919	1919	(BBB) Zolpidem.
1920	1920	944
1921	1921	(iii) Any material, compound, mixture, or preparation of fenfluramine which contains
1922	1922	945
1923	1923	any quantity of the following substances, including its salts, isomers whether
1924	1924	946
1925	1925	optical, position, or geometric, and salts of the isomers when the existence of the
1926	1926	947
1927	1927	salts, isomers, and salts of isomers is possible.
1928	1928	948
1929	1929	(iv) Unless specifically excepted or unless listed in another schedule, any material,
1930	1930	- 28 - 02-21 16:04 H.B. 543
1931	1931	949
1932	1932	compound, mixture, or preparation which contains any quantity of the following
1933	1933	950
1934	1934	substances having a stimulant effect on the central nervous system, including its
1935	1935	951
1936	1936	salts, isomers whether optical, position, or geometric isomers, and salts of the
1937	1937	952
1938	1938	isomers when the existence of the salts, isomers, and salts of isomers is possible
1939	1939	953
1940	1940	within the specific chemical designation:
1941	1941	954
1942	1942	(A) Cathine ((+)-norpseudoephedrine);
1943	1943	955
1944	1944	(B) Diethylpropion;
1945	1945	956
1946	1946	(C) Fencamfamine;
1947	1947	957
1948	1948	(D) Fenproprex;
1949	1949	958
1950	1950	(E) Mazindol;
1951	1951	959
1952	1952	(F) Mefenorex;
1953	1953	960
1954	1954	(G) Modafinil;
1955	1955	961
1956	1956	(H) Pemoline, including organometallic complexes and chelates thereof;
1957	1957	962
1958	1958	(I) Phentermine;
1959	1959	963
1960	1960	(J) Pipradrol;
1961	1961	964
1962	1962	(K) Sibutramine; and
1963	1963	965
1964	1964	(L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
1965	1965	966
1966	1966	(v) Unless specifically excepted or unless listed in another schedule, any material,
1967	1967	967
1968	1968	compound, mixture, or preparation which contains any quantity of
1969	1969	968
1970	1970	dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
1971	1971	969
1972	1972	2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
1973	1973	970
1974	1974	(vi) A drug product or preparation that contains any component of marijuana and is
1975	1975	971
1976	1976	approved by the United States Food and Drug Administration and scheduled by
1977	1977	972
1978	1978	the federal Drug Enforcement Administration in Schedule IV of the federal
1979	1979	973
1980	1980	Controlled Substances Act, Title II, P.L. 91-513.
1981	1981	974
1982	1982	(e) Schedule V:
1983	1983	975
1984	1984	(i) Any compound, mixture, or preparation containing any of the following limited
1985	1985	976
1986	1986	quantities of narcotic drugs, or their salts calculated as the free anhydrous base or
1987	1987	977
1988	1988	alkaloid, which includes one or more non-narcotic active medicinal ingredients in
1989	1989	978
1990	1990	sufficient proportion to confer upon the compound, mixture, or preparation
1991	1991	979
1992	1992	valuable medicinal qualities other than those possessed by the narcotic drug alone:
1993	1993	980
1994	1994	(A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
1995	1995	981
1996	1996	(B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
1997	1997	982
1998	1998	grams;
1999	1999	- 29 - H.B. 543 02-21 16:04
2000	2000	983
2001	2001	(C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
2002	2002	984
2003	2003	grams;
2004	2004	985
2005	2005	(D) not more than 2.5 milligrams of diphenoxylate and not less than 25
2006	2006	986
2007	2007	micrograms of atropine sulfate per dosage unit;
2008	2008	987
2009	2009	(E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
2010	2010	988
2011	2011	(F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
2012	2012	989
2013	2013	atropine sulfate per dosage unit; and
2014	2014	990
2015	2015	(G) unless specifically exempted or excluded or unless listed in another schedule,
2016	2016	991
2017	2017	any material, compound, mixture, or preparation which contains Pyrovalerone
2018	2018	992
2019	2019	having a stimulant effect on the central nervous system, including its salts,
2020	2020	993
2021	2021	isomers, and salts of isomers.
2022	2022	994
2023	2023	(ii) A drug product or preparation that contains any component of marijuana,
2024	2024	995
2025	2025	including cannabidiol, and is approved by the United States Food and Drug
2026	2026	996
2027	2027	Administration and scheduled by the federal Drug Enforcement Administration in
2028	2028	997
2029	2029	Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.
2030	2030	998
2031	2031	(iii) Gabapentin.
2032	2032	999
2033	2033	Section 5. Section 58-37-5.5 is amended to read:
2034	2034	1000
2035	2035	58-37-5.5 (Effective 07/01/25). Recognized controlled substance analogs.
2036	2036	1001
2037	2037	(1) A substance listed under Subsection (2) is an analog, as defined in Subsection [
2038	2038	1002
2039	2039	58-37-2(1)(g)] 58-37-2(1)(h), if the substance, in any quantity, and in any material,
2040	2040	1003
2041	2041	compound, mixture, or preparation, is present in:
2042	2042	1004
2043	2043	(a) any product manufactured, distributed, or possessed for the purpose of human
2044	2044	1005
2045	2045	consumption; or
2046	2046	1006
2047	2047	(b) any product, the use or administration of which results in human consumption.
2048	2048	1007
2049	2049	(2) Substances referred to in Subsection (1) include, but are not limited to:
2050	2050	1008
2051	2051	(a) gamma butyrolactone (GBL);
2052	2052	1009
2053	2053	(b) butyrolactone;
2054	2054	1010
2055	2055	(c) 1,2 butanolide;
2056	2056	1011
2057	2057	(d) 2-oxanolone;
2058	2058	1012
2059	2059	(e) tetrahydro-2-furanone;
2060	2060	1013
2061	2061	(f) dihydro-2 (3H)-furanone;
2062	2062	1014
2063	2063	(g) tetramethylene glycol;
2064	2064	1015
2065	2065	(h) 1,4 butanediol; and
2066	2066	1016
2067	2067	(i) gamma valerolactone.
2068	2068	- 30 - 02-21 16:04 H.B. 543
2069	2069	1017
2070	2070	Section 6. Section 58-37-6 is amended to read:
2071	2071	1018
2072	2072	58-37-6 (Effective 07/01/25). Certified practitioners -- Records required --
2073	2073	1019
2074	2074	Prescriptions.
2075	2075	1020
2076	2076	(1)[(a) The] In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking
2077	2077	1021
2078	2078	Act, the division may adopt rules [relating to the licensing and control of the
2079	2079	1022
2080	2080	manufacture] to control the manufacturing, distribution, production, prescription,
2081	2081	1023
2082	2082	administration, dispensing, conducting of research with, and performing of laboratory
2083	2083	1024
2084	2084	analysis upon controlled substances within this state.
2085	2085	1025
2086	2086	[(b) The division may assess reasonable fees to defray the cost of issuing original and
2087	2087	1026
2088	2088	renewal licenses under this chapter pursuant to Section 63J-1-504.]
2089	2089	1027
2090	2090	[(2)(a)(i) Every person who manufactures, produces, distributes, prescribes,
2091	2091	1028
2092	2092	dispenses, administers, conducts research with, or performs laboratory analysis
2093	2093	1029
2094	2094	upon any controlled substance in Schedules I through V within this state, or who
2095	2095	1030
2096	2096	proposes to engage in manufacturing, producing, distributing, prescribing,
2097	2097	1031
2098	2098	dispensing, administering, conducting research with, or performing laboratory
2099	2099	1032
2100	2100	analysis upon controlled substances included in Schedules I through V within this
2101	2101	1033
2102	2102	state shall obtain a license issued by the division.]
2103	2103	1034
2104	2104	[(ii) The division shall issue each license under this chapter in accordance with a
2105	2105	1035
2106	2106	two-year renewal cycle established by rule. The division may by rule extend or
2107	2107	1036
2108	2108	shorten a renewal period by as much as one year to stagger the renewal cycles it
2109	2109	1037
2110	2110	administers.]
2111	2111	1038
2112	2112	[(b) Persons licensed to manufacture, produce, distribute, prescribe, dispense,
2113	2113	1039
2114	2114	administer, conduct research with, or perform laboratory analysis upon controlled
2115	2115	1040
2116	2116	substances in Schedules I through V within this state may possess, manufacture,
2117	2117	1041
2118	2118	produce, distribute, prescribe, dispense, administer, conduct research with, or
2119	2119	1042
2120	2120	perform laboratory analysis upon those substances to the extent authorized by their
2121	2121	1043
2122	2122	license and in conformity with this chapter.]
2123	2123	1044
2124	2124	[(c) The following persons are not required to obtain a license and may lawfully possess
2125	2125	1045
2126	2126	controlled substances included in Schedules II through V under this section:]
2127	2127	1046
2128	2128	[(i) an agent or employee, except a sales representative, of any registered
2129	2129	1047
2130	2130	manufacturer, distributor, or dispenser of any controlled substance, if the agent or
2131	2131	1048
2132	2132	employee is acting in the usual course of the agent or employee's business or
2133	2133	1049
2134	2134	employment; however, nothing in this subsection shall be interpreted to permit an
2135	2135	1050
2136	2136	agent, employee, sales representative, or detail man to maintain an inventory of
2137	2137	- 31 - H.B. 543 02-21 16:04
2138	2138	1051
2139	2139	controlled substances separate from the location of the person's employer's
2140	2140	1052
2141	2141	registered and licensed place of business;]
2142	2142	1053
2143	2143	[(ii) a motor carrier or warehouseman, or an employee of a motor carrier or
2144	2144	1054
2145	2145	warehouseman, who possesses a controlled substance in the usual course of the
2146	2146	1055
2147	2147	person's business or employment; and]
2148	2148	1056
2149	2149	[(iii) an ultimate user, or a person who possesses any controlled substance pursuant to
2150	2150	1057
2151	2151	a lawful order of a practitioner.]
2152	2152	1058
2153	2153	[(d) The division may enact rules waiving the license requirement for certain
2154	2154	1059
2155	2155	manufacturers, producers, distributors, prescribers, dispensers, administrators,
2156	2156	1060
2157	2157	research practitioners, or laboratories performing analysis if waiving the license
2158	2158	1061
2159	2159	requirement is consistent with public health and safety.]
2160	2160	1062
2161	2161	[(e) A separate license is required at each principal place of business or professional
2162	2162	1063
2163	2163	practice where the applicant manufactures, produces, distributes, dispenses, conducts
2164	2164	1064
2165	2165	research with, or performs laboratory analysis upon controlled substances.]
2166	2166	1065
2167	2167	[(f) The division may enact rules providing for the inspection of a licensee or applicant's
2168	2168	1066
2169	2169	establishment, and may inspect the establishment according to those rules.]
2170	2170	1067
2171	2171	[(3)(a)(i) Upon proper application, the division shall license a qualified applicant to
2172	2172	1068
2173	2173	manufacture, produce, distribute, conduct research with, or perform laboratory
2174	2174	1069
2175	2175	analysis upon controlled substances included in Schedules I through V, unless it
2176	2176	1070
2177	2177	determines that issuance of a license is inconsistent with the public interest.]
2178	2178	1071
2179	2179	[(ii) The division may not issue a license to any person to prescribe, dispense, or
2180	2180	1072
2181	2181	administer a Schedule I controlled substance except under Subsection (3)(a)(i).]
2182	2182	1073
2183	2183	[(iii) In determining public interest under this Subsection (3)(a), the division shall
2184	2184	1074
2185	2185	consider whether the applicant has:]
2186	2186	1075
2187	2187	[(A) maintained effective controls against diversion of controlled substances and
2188	2188	1076
2189	2189	any Schedule I or II substance compounded from any controlled substance into
2190	2190	1077
2191	2191	channels other than legitimate medical, scientific, or industrial channels;]
2192	2192	1078
2193	2193	[(B) complied with applicable state and local law;]
2194	2194	1079
2195	2195	[(C) been convicted under federal or state laws relating to the manufacture,
2196	2196	1080
2197	2197	distribution, or dispensing of substances;]
2198	2198	1081
2199	2199	[(D) past experience in the manufacture of controlled dangerous substances;]
2200	2200	1082
2201	2201	[(E) established effective controls against diversion; and]
2202	2202	1083
2203	2203	[(F) complied with any other factors that the division establishes that promote the
2204	2204	1084
2205	2205	public health and safety.]
2206	2206	- 32 - 02-21 16:04 H.B. 543
2207	2207	1085
2208	2208	[(b) Licenses granted under Subsection (3)(a) do not entitle a licensee to manufacture,
2209	2209	1086
2210	2210	produce, distribute, conduct research with, or perform laboratory analysis upon
2211	2211	1087
2212	2212	controlled substances in Schedule I other than those specified in the license.]
2213	2213	1088
2214	2214	[(c)(i) Practitioners shall be licensed to administer, dispense, or conduct research
2215	2215	1089
2216	2216	with substances in Schedules II through V if they are authorized to administer,
2217	2217	1090
2218	2218	dispense, or conduct research under the laws of this state.]
2219	2219	1091
2220	2220	[(ii) The division need not require a separate license for practitioners engaging in
2221	2221	1092
2222	2222	research with nonnarcotic controlled substances in Schedules II through V where
2223	2223	1093
2224	2224	the licensee is already licensed under this chapter in another capacity.]
2225	2225	1094
2226	2226	[(iii) With respect to research involving narcotic substances in Schedules II through
2227	2227	1095
2228	2228	V, or where the division by rule requires a separate license for research of
2229	2229	1096
2230	2230	nonnarcotic substances in Schedules II through V, a practitioner shall apply to the
2231	2231	1097
2232	2232	division prior to conducting research.]
2233	2233	1098
2234	2234	[(iv) Licensing for purposes of bona fide research with controlled substances by a
2235	2235	1099
2236	2236	practitioner considered qualified may be denied only on a ground specified in
2237	2237	1100
2238	2238	Subsection (4), or upon evidence that the applicant will abuse or unlawfully
2239	2239	1101
2240	2240	transfer or fail to safeguard adequately the practitioner's supply of substances
2241	2241	1102
2242	2242	against diversion from medical or scientific use.]
2243	2243	1103
2244	2244	[(v) Practitioners registered under federal law to conduct research in Schedule I
2245	2245	1104
2246	2246	substances may conduct research in Schedule I substances within this state upon
2247	2247	1105
2248	2248	providing the division with evidence of federal registration.]
2249	2249	1106
2250	2250	[(d) Compliance by manufacturers, producers, and distributors with the provisions of
2251	2251	1107
2252	2252	federal law respecting registration, excluding fees, entitles them to be licensed under
2253	2253	1108
2254	2254	this chapter.]
2255	2255	1109
2256	2256	[(e) The division shall initially license those persons who own or operate an
2257	2257	1110
2258	2258	establishment engaged in the manufacture, production, distribution, dispensation, or
2259	2259	1111
2260	2260	administration of controlled substances prior to April 3, 1980, and who are licensed
2261	2261	1112
2262	2262	by the state.]
2263	2263	1113
2264	2264	[(4)] (2)(a) [Any license issued pursuant to Subsection (2) or (3) may be denied,
2265	2265	1114
2266	2266	suspended, placed on probation, or revoked by the division] The division or an
2267	2267	1115
2268	2268	applicable professional licensing board may limit, suspend, place on probation, or
2269	2269	1116
2270	2270	revoke a practitioner's controlled substance certification upon finding that the [
2271	2271	1117
2272	2272	applicant or licensee] practitioner has:
2273	2273	1118
2274	2274	(i) materially falsified any application filed or required pursuant to this chapter;
2275	2275	- 33 - H.B. 543 02-21 16:04
2276	2276	1119
2277	2277	(ii) been convicted of an offense under this chapter or any law of the United States, or
2278	2278	1120
2279	2279	any state, relating to any substance defined as a controlled substance;
2280	2280	1121
2281	2281	(iii) been convicted of a felony under any other law of the United States or any state
2282	2282	1122
2283	2283	within five years of the date of the [issuance of the license] division's action;
2284	2284	1123
2285	2285	(iv) had a federal registration or license denied, suspended, or revoked by competent
2286	2286	1124
2287	2287	federal authority and is no longer authorized to manufacture, distribute, prescribe,
2288	2288	1125
2289	2289	or dispense controlled substances;
2290	2290	1126
2291	2291	(v) had the [licensee's] practitioner's license suspended, placed on probation, or
2292	2292	1127
2293	2293	revoked by competent authority of another state for violation of laws or
2294	2294	1128
2295	2295	regulations comparable to those of this state relating to the manufacture,
2296	2296	1129
2297	2297	distribution, or dispensing of controlled substances;
2298	2298	1130
2299	2299	(vi) violated any division rule that reflects adversely on the [licensee's] practitioner's
2300	2300	1131
2301	2301	reliability and integrity with respect to controlled substances;
2302	2302	1132
2303	2303	(vii) refused inspection of records required to be maintained under this chapter by a
2304	2304	1133
2305	2305	person authorized to inspect them; or
2306	2306	1134
2307	2307	(viii) prescribed, dispensed, administered, or injected an anabolic steroid for the
2308	2308	1135
2309	2309	purpose of manipulating human hormonal structure so as to:
2310	2310	1136
2311	2311	(A) increase muscle mass, strength, or weight without medical necessity and
2312	2312	1137
2313	2313	without a written prescription by any practitioner in the course of the
2314	2314	1138
2315	2315	practitioner's professional practice; or
2316	2316	1139
2317	2317	(B) improve performance in any form of human exercise, sport, or game.
2318	2318	1140
2319	2319	(b) If the division or a professional licensing board limits, suspends, places on probation,
2320	2320	1141
2321	2321	or revokes a practitioner's controlled substance certification, the division shall enter
2322	2322	1142
2323	2323	that action in the controlled substance database created in Section 58-37f-201 and
2324	2324	1143
2325	2325	notify the federal Drug Enforcement Administration of that action.
2326	2326	1144
2327	2327	(c) If a practitioner distributes, dispenses, or administers a controlled substance without
2328	2328	1145
2329	2329	a controlled substance certification or in violation of a limitation, suspension, or
2330	2330	1146
2331	2331	probation under Subsection (2)(b), the division or the applicable professional
2332	2332	1147
2333	2333	licensing board may suspend, restrict, place on probation, or otherwise act upon the
2334	2334	1148
2335	2335	practitioner's professional license.
2336	2336	1149
2337	2337	[(b) The division may limit revocation or suspension of a license to a particular
2338	2338	1150
2339	2339	controlled substance with respect to which grounds for revocation or suspension exist.]
2340	2340	1151
2341	2341	[(c)(i) Proceedings to deny, revoke, or suspend a license shall be conducted pursuant
2342	2342	1152
2343	2343	to this section and in accordance with the procedures set forth in Title 58, Chapter
2344	2344	- 34 - 02-21 16:04 H.B. 543
2345	2345	1153
2346	2346	1, Division of Professional Licensing Act, and conducted in conjunction with the
2347	2347	1154
2348	2348	appropriate representative committee designated by the director of the department.]
2349	2349	1155
2350	2350	[(ii) Nothing in this Subsection (4)(c) gives the Division of Professional Licensing
2351	2351	1156
2352	2352	exclusive authority in proceedings to deny, revoke, or suspend licenses, except
2353	2353	1157
2354	2354	where the division is designated by law to perform those functions, or, when not
2355	2355	1158
2356	2356	designated by law, is designated by the executive director of the Department of
2357	2357	1159
2358	2358	Commerce to conduct the proceedings.]
2359	2359	1160
2360	2360	[(d)(i) The division may suspend any license simultaneously with the institution of
2361	2361	1161
2362	2362	proceedings under this section if it finds there is an imminent danger to the public
2363	2363	1162
2364	2364	health or safety.]
2365	2365	1163
2366	2366	[(ii) Suspension shall continue in effect until the conclusion of proceedings, including
2367	2367	1164
2368	2368	judicial review, unless withdrawn by the division or dissolved by a court of
2369	2369	1165
2370	2370	competent jurisdiction.]
2371	2371	1166
2372	2372	[(e)(i) If a license is suspended or revoked under this Subsection (4), all controlled
2373	2373	1167
2374	2374	substances owned or possessed by the licensee may be placed under seal in the
2375	2375	1168
2376	2376	discretion of the division.]
2377	2377	1169
2378	2378	[(ii) Disposition may not be made of substances under seal until the time for taking
2379	2379	1170
2380	2380	an appeal has lapsed, or until all appeals have been concluded, unless a court,
2381	2381	1171
2382	2382	upon application, orders the sale of perishable substances and the proceeds
2383	2383	1172
2384	2384	deposited with the court.]
2385	2385	1173
2386	2386	[(iii) If a revocation order becomes final, all controlled substances shall be forfeited.]
2387	2387	1174
2388	2388	[(f) The division shall notify promptly the Drug Enforcement Administration of all
2389	2389	1175
2390	2390	orders suspending or revoking a license and all forfeitures of controlled substances.]
2391	2391	1176
2392	2392	[(g) If an individual's Drug Enforcement Administration registration is denied, revoked,
2393	2393	1177
2394	2394	surrendered, or suspended, the division shall immediately suspend the individual's
2395	2395	1178
2396	2396	controlled substance license, which shall only be reinstated by the division upon
2397	2397	1179
2398	2398	reinstatement of the federal registration, unless the division has taken further
2399	2399	1180
2400	2400	administrative action under Subsection (4)(a)(iv), which would be grounds for the
2401	2401	1181
2402	2402	continued denial of the controlled substance license.]
2403	2403	1182
2404	2404	[(5)] (3)[(a) A person licensed under Subsection (2) or (3)] A practitioner shall maintain
2405	2405	1183
2406	2406	records and inventories in conformance with the record keeping and inventory
2407	2407	1184
2408	2408	requirements of federal and state law and any additional rules issued by the division.
2409	2409	1185
2410	2410	[(b)(i) A physician, dentist, naturopathic physician, veterinarian, practitioner, or
2411	2411	1186
2412	2412	other individual who is authorized to administer or professionally use a controlled
2413	2413	- 35 - H.B. 543 02-21 16:04
2414	2414	1187
2415	2415	substance shall keep a record of the drugs received by the individual and a record
2416	2416	1188
2417	2417	of all drugs administered, dispensed, or professionally used by the individual
2418	2418	1189
2419	2419	otherwise than by a prescription.]
2420	2420	1190
2421	2421	[(ii) An individual using small quantities or solutions or other preparations of those
2422	2422	1191
2423	2423	drugs for local application has complied with this Subsection (5)(b) if the
2424	2424	1192
2425	2425	individual keeps a record of the quantity, character, and potency of those solutions
2426	2426	1193
2427	2427	or preparations purchased or prepared by the individual, and of the dates when
2428	2428	1194
2429	2429	purchased or prepared.]
2430	2430	1195
2431	2431	[(6)] (4) Controlled substances in Schedules I through V may be distributed only by a [
2432	2432	1196
2433	2433	licensee and] certified practitioner and pursuant to an order form prepared in compliance
2434	2434	1197
2435	2435	with division rules or a lawful order under the rules and regulations of the United States.
2436	2436	1198
2437	2437	[(7)] (5)(a) An individual may not write or authorize a prescription for a controlled
2438	2438	1199
2439	2439	substance unless the individual is[:]
2440	2440	1200
2441	2441	[(i)] a practitioner authorized to prescribe drugs and medicine under the laws of this
2442	2442	1201
2443	2443	state or under the laws of another state having similar standards[; and] .
2444	2444	1202
2445	2445	[(ii) licensed under this chapter or under the laws of another state having similar
2446	2446	1203
2447	2447	standards.]
2448	2448	1204
2449	2449	(b) An individual other than a pharmacist licensed under the laws of this state, or the
2450	2450	1205
2451	2451	pharmacist's licensed intern, as required by Sections 58-17b-303 and 58-17b-304,
2452	2452	1206
2453	2453	may not dispense a controlled substance.
2454	2454	1207
2455	2455	(c)(i) A controlled substance may not be dispensed without the written prescription of
2456	2456	1208
2457	2457	a practitioner, if the written prescription is required by the federal Controlled
2458	2458	1209
2459	2459	Substances Act.
2460	2460	1210
2461	2461	(ii) That written prescription shall be made in accordance with Subsection [(7)(a)]
2462	2462	1211
2463	2463	(5)(a) and in conformity with Subsection [(7)(d)] (5)(d).
2464	2464	1212
2465	2465	(iii) In emergency situations, as defined by division rule, controlled substances may
2466	2466	1213
2467	2467	be dispensed upon oral prescription of a practitioner, if reduced promptly to
2468	2468	1214
2469	2469	writing on forms designated by the division and filed by the pharmacy.
2470	2470	1215
2471	2471	(iv) Prescriptions reduced to writing by a pharmacist shall be in conformity with
2472	2472	1216
2473	2473	Subsection [(7)(d)] (5)(d).
2474	2474	1217
2475	2475	(d) Except for emergency situations designated by the division, an individual may not
2476	2476	1218
2477	2477	issue, fill, compound, or dispense a prescription for a controlled substance unless the
2478	2478	1219
2479	2479	prescription is signed by the prescriber in ink or indelible pencil or is signed with an
2480	2480	1220
2481	2481	electronic signature of the prescriber as authorized by division rule, and contains the
2482	2482	- 36 - 02-21 16:04 H.B. 543
2483	2483	1221
2484	2484	following information:
2485	2485	1222
2486	2486	(i) the name, address, and registry number of the prescriber;
2487	2487	1223
2488	2488	(ii) the name, address, and age of the person to whom or for whom the prescription is
2489	2489	1224
2490	2490	issued;
2491	2491	1225
2492	2492	(iii) the date of issuance of the prescription; and
2493	2493	1226
2494	2494	(iv) the name, quantity, and specific directions for use by the ultimate user of the
2495	2495	1227
2496	2496	controlled substance.
2497	2497	1228
2498	2498	(e) A prescription may not be written, issued, filled, or dispensed for a Schedule I
2499	2499	1229
2500	2500	controlled substance unless:
2501	2501	1230
2502	2502	(i) the individual who writes the prescription is [licensed under Subsection (2)] a
2503	2503	1231
2504	2504	certified practitioner; and
2505	2505	1232
2506	2506	(ii) the prescribed controlled substance is to be used in research.
2507	2507	1233
2508	2508	(f) Except when administered directly to an ultimate user by a [licensed ] certified
2509	2509	1234
2510	2510	practitioner, controlled substances are subject to the restrictions of this Subsection [
2511	2511	1235
2512	2512	(7)(f)] (5)(f).
2513	2513	1236
2514	2514	(i) A prescription for a Schedule II substance may not be refilled.
2515	2515	1237
2516	2516	(ii) A Schedule II controlled substance may not be filled in a quantity to exceed a
2517	2517	1238
2518	2518	one-month's supply, as directed on the daily dosage rate of the prescriptions.
2519	2519	1239
2520	2520	(iii)(A) A prescription for a Schedule II or Schedule III controlled substance that
2521	2521	1240
2522	2522	is an opiate and that is issued for an acute condition shall be completely or
2523	2523	1241
2524	2524	partially filled in a quantity not to exceed a seven-day supply as directed on the
2525	2525	1242
2526	2526	daily dosage rate of the prescription.
2527	2527	1243
2528	2528	(B) Subsection [(7)(f)(iii)(A)] (5)(f)(iii)(A) does not apply to prescriptions issued
2529	2529	1244
2530	2530	for complex or chronic conditions which are documented as being complex or
2531	2531	1245
2532	2532	chronic in the medical record.
2533	2533	1246
2534	2534	(C) A pharmacist is not required to verify that a prescription is in compliance with
2535	2535	1247
2536	2536	this Subsection [(7)(f)(iii)] (5)(f)(iii).
2537	2537	1248
2538	2538	(iv) A Schedule III or IV controlled substance may be filled only within six months
2539	2539	1249
2540	2540	of issuance, and may not be refilled more than six months after the date of its
2541	2541	1250
2542	2542	original issuance or be refilled more than five times after the date of the
2543	2543	1251
2544	2544	prescription unless renewed by the practitioner.
2545	2545	1252
2546	2546	(v) All other controlled substances in Schedule V may be refilled as the prescriber's
2547	2547	1253
2548	2548	prescription directs, but they may not be refilled one year after the date the
2549	2549	1254
2550	2550	prescription was issued unless renewed by the certified practitioner.
2551	2551	- 37 - H.B. 543 02-21 16:04
2552	2552	1255
2553	2553	(vi) Any prescription for a Schedule II substance may not be dispensed if it is not
2554	2554	1256
2555	2555	presented to a pharmacist for dispensing by a pharmacist or a pharmacy intern
2556	2556	1257
2557	2557	within 30 days after the date the prescription was issued, or 30 days after the
2558	2558	1258
2559	2559	dispensing date, if that date is specified separately from the date of issue.
2560	2560	1259
2561	2561	(vii) A certified practitioner may issue more than one prescription at the same time
2562	2562	1260
2563	2563	for the same Schedule II controlled substance, but only under the following
2564	2564	1261
2565	2565	conditions:
2566	2566	1262
2567	2567	(A) no more than three prescriptions for the same Schedule II controlled substance
2568	2568	1263
2569	2569	may be issued at the same time;
2570	2570	1264
2571	2571	(B) no one prescription may exceed a 30-day supply; and
2572	2572	1265
2573	2573	(C) a second or third prescription shall include the date of issuance and the date
2574	2574	1266
2575	2575	for dispensing.
2576	2576	1267
2577	2577	(g) An order for a controlled substance in Schedules II through V for use by an inpatient
2578	2578	1268
2579	2579	or an outpatient of a licensed hospital is exempt from all requirements of this
2580	2580	1269
2581	2581	Subsection [(7)] (5) if the order is:
2582	2582	1270
2583	2583	(i) issued or made by a prescribing practitioner who holds an unrestricted registration
2584	2584	1271
2585	2585	with the federal Drug Enforcement Administration[, and an active Utah controlled
2586	2586	1272
2587	2587	substance license in good standing issued by the division under this section, or a
2588	2588	1273
2589	2589	medical resident who is exempted from licensure under Subsection 58-1-307(1)(c)];
2590	2590	1274
2591	2591	(ii) authorized by the prescribing practitioner treating the patient and the prescribing
2592	2592	1275
2593	2593	practitioner designates the quantity ordered;
2594	2594	1276
2595	2595	(iii) entered upon the record of the patient, the record is signed by the prescriber
2596	2596	1277
2597	2597	affirming the prescriber's authorization of the order within 48 hours after filling or
2598	2598	1278
2599	2599	administering the order, and the patient's record reflects the quantity actually
2600	2600	1279
2601	2601	administered; and
2602	2602	1280
2603	2603	(iv) filled and dispensed by a pharmacist practicing the pharmacist's profession
2604	2604	1281
2605	2605	within the physical structure of the hospital, or the order is taken from a supply
2606	2606	1282
2607	2607	lawfully maintained by the hospital and the amount taken from the supply is
2608	2608	1283
2609	2609	administered directly to the patient authorized to receive it.
2610	2610	1284
2611	2611	(h)(i) A certified practitioner [licensed under this chapter ]may not prescribe,
2612	2612	1285
2613	2613	administer, or dispense a controlled substance to a child[,] without first obtaining
2614	2614	1286
2615	2615	the consent required in Section 78B-3-406 of a parent, guardian, or person
2616	2616	1287
2617	2617	standing in loco parentis of the child except in cases of an emergency.
2618	2618	1288
2619	2619	(ii) For purposes of this Subsection [(7)(h), "child"] (5)(h):
2620	2620	- 38 - 02-21 16:04 H.B. 543
2621	2621	1289
2622	2622	(A) [has the same meaning as] "Child" means the same as that term is defined in
2623	2623	1290
2624	2624	Section 80-1-102[, and "emergency"] .
2625	2625	1291
2626	2626	(B) "Emergency" means any physical condition requiring the administration of a
2627	2627	1292
2628	2628	controlled substance for immediate relief of pain or suffering.
2629	2629	1293
2630	2630	(i) A certified practitioner [licensed under this chapter ]may not prescribe or administer
2631	2631	1294
2632	2632	dosages of a controlled substance in excess of medically recognized quantities
2633	2633	1295
2634	2634	necessary to treat the ailment, malady, or condition of the ultimate user.
2635	2635	1296
2636	2636	(j) A certified practitioner [licensed under this chapter ]may not prescribe, administer, or
2637	2637	1297
2638	2638	dispense any controlled substance to another person knowing that the other person is
2639	2639	1298
2640	2640	using a false name, address, or other personal information for the purpose of securing
2641	2641	1299
2642	2642	the controlled substance.
2643	2643	1300
2644	2644	[(k) A person who is licensed under this chapter to manufacture, distribute, or dispense a
2645	2645	1301
2646	2646	controlled substance may not manufacture, distribute, or dispense a controlled
2647	2647	1302
2648	2648	substance to another licensee or any other authorized person not authorized by this
2649	2649	1303
2650	2650	license.]
2651	2651	1304
2652	2652	[(l)] (k) A [person licensed under this chapter] certified practitioner may not omit,
2653	2653	1305
2654	2654	remove, alter, or obliterate a symbol required by this chapter or by a rule issued under
2655	2655	1306
2656	2656	this chapter.
2657	2657	1307
2658	2658	[(m)] (l) A [person licensed under this chapter] certified practitioner may not refuse or fail
2659	2659	1308
2660	2660	to make, keep, or furnish any record notification, order form, statement, invoice, or
2661	2661	1309
2662	2662	information required under this chapter.
2663	2663	1310
2664	2664	[(n)] (m) A [person licensed under this chapter] certified practitioner may not refuse entry
2665	2665	1311
2666	2666	into any premises for inspection as authorized by this chapter.
2667	2667	1312
2668	2668	[(o)] (n) A [person licensed under this chapter] certified practitioner may not furnish false
2669	2669	1313
2670	2670	or fraudulent material information in any application, report, or other document
2671	2671	1314
2672	2672	required to be kept by this chapter or willfully make any false statement in any
2673	2673	1315
2674	2674	prescription, order, report, or record required by this chapter.
2675	2675	1316
2676	2676	[(8)] (6)(a)(i) Any [person licensed under this chapter] certified practitioner who is
2677	2677	1317
2678	2678	found by the division to have violated any of the provisions of Subsections [(7)(k)
2679	2679	1318
2680	2680	through (o) or Subsection (10)] (5)(k) through (n) is subject to a penalty not to
2681	2681	1319
2682	2682	exceed $5,000.
2683	2683	1320
2684	2684	(ii) The division shall determine the procedure for adjudication of any violations in
2685	2685	1321
2686	2686	accordance with Sections 58-1-106 and 58-1-108.
2687	2687	1322
2688	2688	[(ii)] (iii) The division shall deposit all penalties collected under Subsection [(8)(a)(i)]
2689	2689	- 39 - H.B. 543 02-21 16:04
2690	2690	1323
2691	2691	(6)(a)(i) into the General Fund as a dedicated credit to be used by the division
2692	2692	1324
2693	2693	under Subsection 58-37f-502(1).
2694	2694	1325
2695	2695	[(iii)] (iv) The director may collect a penalty that is not paid by:
2696	2696	1326
2697	2697	(A) referring the matter to a collection agency; or
2698	2698	1327
2699	2699	(B) bringing an action in the district court of the county where the person against
2700	2700	1328
2701	2701	whom the penalty is imposed resides or in the county where the office of the
2702	2702	1329
2703	2703	director is located.
2704	2704	1330
2705	2705	[(iv)] (v) A county attorney or the attorney general of the state shall provide legal
2706	2706	1331
2707	2707	assistance and advice to the director in an action to collect a penalty.
2708	2708	1332
2709	2709	[(v)] (vi) A court shall award reasonable attorney fees and costs to the prevailing party
2710	2710	1333
2711	2711	in an action brought by the division to collect a penalty.
2712	2712	1334
2713	2713	(b) Any person who knowingly and intentionally violates Subsections [(7)(h)] (5)(h)
2714	2714	1335
2715	2715	through (j)[ or Subsection (10)] is:
2716	2716	1336
2717	2717	(i) upon first conviction, guilty of a class B misdemeanor;
2718	2718	1337
2719	2719	(ii) upon second conviction, guilty of a class A misdemeanor; and
2720	2720	1338
2721	2721	(iii) on third or subsequent conviction, guilty of a third degree felony.
2722	2722	1339
2723	2723	(c) Any person who knowingly and intentionally violates Subsections [(7)(k) through (o)]
2724	2724	1340
2725	2725	(5)(k) through (n) shall upon conviction be guilty of a third degree felony.
2726	2726	1341
2727	2727	[(9)] (7) Any information communicated to any [licensed ] certified practitioner in an
2728	2728	1342
2729	2729	attempt to unlawfully procure, or to procure the administration of, a controlled substance
2730	2730	1343
2731	2731	is not considered to be a privileged communication.
2732	2732	1344
2733	2733	[(10) A person holding a valid license under this chapter who is engaged in medical
2734	2734	1345
2735	2735	research may produce, possess, administer, prescribe, or dispense a controlled substance
2736	2736	1346
2737	2737	for research purposes as licensed under Subsection (2) but may not otherwise prescribe
2738	2738	1347
2739	2739	or dispense a controlled substance listed in Section 58-37-4.2.]
2740	2740	1348
2741	2741	[(11)] (8)(a) As used in this Subsection [(11)] (8):
2742	2742	1349
2743	2743	(i) "High risk prescription" means a prescription for an opiate or a benzodiazepine
2744	2744	1350
2745	2745	that is written to continue for longer than 30 consecutive days.
2746	2746	1351
2747	2747	(ii) "Database" means the controlled substance database created in Section 58-37f-201.
2748	2748	1352
2749	2749	(b) A certified practitioner who issues a high risk prescription to a patient shall, before
2750	2750	1353
2751	2751	issuing the high risk prescription to the patient, verify in the database that the patient
2752	2752	1354
2753	2753	does not have a high risk prescription from a different practitioner that is currently
2754	2754	1355
2755	2755	active.
2756	2756	1356
2757	2757	(c) If the database shows that the patient has received a high risk prescription that is
2758	2758	- 40 - 02-21 16:04 H.B. 543
2759	2759	1357
2760	2760	currently active from a different practitioner, the certified practitioner may not issue a
2761	2761	1358
2762	2762	high risk prescription to the patient unless the certified practitioner:
2763	2763	1359
2764	2764	(i) contacts and consults with each practitioner who issued a high risk prescription
2765	2765	1360
2766	2766	that is currently active to the patient;
2767	2767	1361
2768	2768	(ii) documents in the patient's medical record that the certified practitioner made
2769	2769	1362
2770	2770	contact with each practitioner in accordance with Subsection [(11)(c)(i)] (8)(c)(i);
2771	2771	1363
2772	2772	and
2773	2773	1364
2774	2774	(iii) documents in the patient's medical record the reason why the certified
2775	2775	1365
2776	2776	practitioner believes that the patient needs multiple high risk prescriptions from
2777	2777	1366
2778	2778	different practitioners.
2779	2779	1367
2780	2780	(d) A certified practitioner shall satisfy the requirement described in Subsection [(11)(c)]
2781	2781	1368
2782	2782	(8)(c) in a timely manner, which may be after the practitioner issues the high risk
2783	2783	1369
2784	2784	prescription to the patient.
2785	2785	1370
2786	2786	Section 7. Section 58-37-8 is amended to read:
2787	2787	1371
2788	2788	58-37-8 (Effective 07/01/25). Prohibited acts -- Penalties.
2789	2789	1372
2790	2790	(1) Prohibited acts A -- Penalties and reporting:
2791	2791	1373
2792	2792	(a) Except as authorized by this chapter, it is unlawful for a person to knowingly and
2793	2793	1374
2794	2794	intentionally:
2795	2795	1375
2796	2796	(i) produce, manufacture, or dispense, or to possess with intent to produce,
2797	2797	1376
2798	2798	manufacture, or dispense, a controlled or counterfeit substance;
2799	2799	1377
2800	2800	(ii) distribute a controlled or counterfeit substance, or to agree, consent, offer, or
2801	2801	1378
2802	2802	arrange to distribute a controlled or counterfeit substance;
2803	2803	1379
2804	2804	(iii) possess a controlled or counterfeit substance with intent to distribute; or
2805	2805	1380
2806	2806	(iv) engage in a continuing criminal enterprise where:
2807	2807	1381
2808	2808	(A) the person participates, directs, or engages in conduct that results in a
2809	2809	1382
2810	2810	violation of this chapter, Chapter 37a, Utah Drug Paraphernalia Act, Chapter
2811	2811	1383
2812	2812	37b, Imitation Controlled Substances Act, Chapter 37c, Utah Controlled
2813	2813	1384
2814	2814	Substance Precursor Act, or Chapter 37d, Clandestine Drug Lab Act, that is a
2815	2815	1385
2816	2816	felony; and
2817	2817	1386
2818	2818	(B) the violation is a part of a continuing series of two or more violations of this
2819	2819	1387
2820	2820	chapter, Chapter 37a, Utah Drug Paraphernalia Act, Chapter 37b, Imitation
2821	2821	1388
2822	2822	Controlled Substances Act, Chapter 37c, Utah Controlled Substance Precursor
2823	2823	1389
2824	2824	Act, or Chapter 37d, Clandestine Drug Lab Act, on separate occasions that are
2825	2825	1390
2826	2826	undertaken in concert with five or more persons with respect to whom the
2827	2827	- 41 - H.B. 543 02-21 16:04
2828	2828	1391
2829	2829	person occupies a position of organizer, supervisor, or any other position of
2830	2830	1392
2831	2831	management.
2832	2832	1393
2833	2833	(b) A person convicted of violating Subsection (1)(a) with respect to:
2834	2834	1394
2835	2835	(i) a substance or a counterfeit of a substance classified in Schedule I or II, a
2836	2836	1395
2837	2837	controlled substance analog, or gammahydroxybutyric acid as listed in Schedule
2838	2838	1396
2839	2839	III is guilty of a second degree felony, punishable by imprisonment for not more
2840	2840	1397
2841	2841	than 15 years, and upon a second or subsequent conviction is guilty of a first
2842	2842	1398
2843	2843	degree felony;
2844	2844	1399
2845	2845	(ii) a substance or a counterfeit of a substance classified in Schedule III or IV, or
2846	2846	1400
2847	2847	marijuana, or a substance listed in Section 58-37-4.2 is guilty of a third degree
2848	2848	1401
2849	2849	felony, and upon a second or subsequent conviction is guilty of a second degree
2850	2850	1402
2851	2851	felony; or
2852	2852	1403
2853	2853	(iii) a substance or a counterfeit of a substance classified in Schedule V is guilty of a
2854	2854	1404
2855	2855	class A misdemeanor and upon a second or subsequent conviction is guilty of a
2856	2856	1405
2857	2857	third degree felony.
2858	2858	1406
2859	2859	(c)(i) Except as provided in Subsection (1)(c)(ii), a person who has been convicted of
2860	2860	1407
2861	2861	a violation of Subsection (1)(a)(ii) or (iii) may be sentenced to imprisonment for
2862	2862	1408
2863	2863	an indeterminate term as described in Subsection [(1)(b)] (1)(c)(ii) and Title 76,
2864	2864	1409
2865	2865	Chapter 3, Punishments.
2866	2866	1410
2867	2867	(ii) The court shall impose an indeterminate prison term for a person who has been
2868	2868	1411
2869	2869	convicted of a violation of Subsection (1)(a)(ii) or (iii) that is a first degree felony
2870	2870	1412
2871	2871	or a second degree felony if the trier of fact finds beyond a reasonable doubt that,
2872	2872	1413
2873	2873	during the commission or furtherance of the violation, the person intentionally or
2874	2874	1414
2875	2875	knowingly:
2876	2876	1415
2877	2877	(A) used, drew, or exhibited a dangerous weapon, as that term is defined in
2878	2878	1416
2879	2879	Section 76-10-501, that is not a firearm, in an angry, threatening, intimidating,
2880	2880	1417
2881	2881	or coercive manner;
2882	2882	1418
2883	2883	(B) used a firearm or had a firearm readily accessible for immediate use, as those
2884	2884	1419
2885	2885	terms are defined in Section 76-10-501; or
2886	2886	1420
2887	2887	(C) distributed a firearm, as that term is defined in Section 76-10-501, or
2888	2888	1421
2889	2889	possessed a firearm with intent to distribute the firearm.
2890	2890	1422
2891	2891	(iii) Notwithstanding Subsection (1)(c)(ii), a court may suspend the indeterminate
2892	2892	1423
2893	2893	prison term for a person convicted under Subsection (1)(c)(ii) if the court:
2894	2894	1424
2895	2895	(A) details on the record the reasons why it is in the interests of justice not to
2896	2896	- 42 - 02-21 16:04 H.B. 543
2897	2897	1425
2898	2898	impose the indeterminate prison term;
2899	2899	1426
2900	2900	(B) makes a finding on the record that the person does not pose a significant
2901	2901	1427
2902	2902	safety risk to the public; and
2903	2903	1428
2904	2904	(C) orders the person to complete the terms and conditions of supervised
2905	2905	1429
2906	2906	probation provided by the Department of Corrections.
2907	2907	1430
2908	2908	(d)(i) A person convicted of violating Subsection (1)(a)(iv) is guilty of a first degree
2909	2909	1431
2910	2910	felony punishable by imprisonment for an indeterminate term of not less than:
2911	2911	1432
2912	2912	(A) seven years and which may be for life; or
2913	2913	1433
2914	2914	(B) 15 years and which may be for life if the trier of fact determined that the
2915	2915	1434
2916	2916	defendant knew or reasonably should have known that any subordinate under
2917	2917	1435
2918	2918	Subsection (1)(a)(iv)(B) was under 18 years old.
2919	2919	1436
2920	2920	(ii) Imposition or execution of the sentence may not be suspended, and the person is
2921	2921	1437
2922	2922	not eligible for probation.
2923	2923	1438
2924	2924	(iii) Subsection (1)(d)(i)(B) does not apply to any defendant who, at the time of the
2925	2925	1439
2926	2926	offense, was under 18 years old.
2927	2927	1440
2928	2928	(e) The Administrative Office of the Courts shall report to the Division of Professional
2929	2929	1441
2930	2930	Licensing the name, case number, date of conviction, and if known, the date of birth
2931	2931	1442
2932	2932	of each person convicted of violating Subsection (1)(a).
2933	2933	1443
2934	2934	(2) Prohibited acts B -- Penalties and reporting:
2935	2935	1444
2936	2936	(a) It is unlawful:
2937	2937	1445
2938	2938	(i) for a person knowingly and intentionally to possess or use a controlled substance
2939	2939	1446
2940	2940	analog or a controlled substance, unless it was obtained under a valid prescription
2941	2941	1447
2942	2942	or order, directly from a practitioner while acting in the course of the person's
2943	2943	1448
2944	2944	professional practice, or as otherwise authorized by this chapter;
2945	2945	1449
2946	2946	(ii) for an owner, tenant, licensee, or person in control of a building, room, tenement,
2947	2947	1450
2948	2948	vehicle, boat, aircraft, or other place knowingly and intentionally to permit them
2949	2949	1451
2950	2950	to be occupied by persons unlawfully possessing, using, or distributing controlled
2951	2951	1452
2952	2952	substances in any of those locations; or
2953	2953	1453
2954	2954	(iii) for a person knowingly and intentionally to possess an altered or forged
2955	2955	1454
2956	2956	prescription or written order for a controlled substance.
2957	2957	1455
2958	2958	(b) A person convicted of violating Subsection (2)(a)(i) with respect to:
2959	2959	1456
2960	2960	(i) marijuana, if the amount is 100 pounds or more, is guilty of a second degree
2961	2961	1457
2962	2962	felony; or
2963	2963	1458
2964	2964	(ii) a substance classified in Schedule I or II, or a controlled substance analog, is
2965	2965	- 43 - H.B. 543 02-21 16:04
2966	2966	1459
2967	2967	guilty of a class A misdemeanor on a first or second conviction, and on a third or
2968	2968	1460
2969	2969	subsequent conviction if each prior offense was committed within seven years
2970	2970	1461
2971	2971	before the date of the offense upon which the current conviction is based is guilty
2972	2972	1462
2973	2973	of a third degree felony.
2974	2974	1463
2975	2975	(c) Upon a person's conviction of a violation of this Subsection (2) subsequent to a
2976	2976	1464
2977	2977	conviction under Subsection (1)(a), that person shall be sentenced to a one degree
2978	2978	1465
2979	2979	greater penalty than provided in this Subsection (2).
2980	2980	1466
2981	2981	(d)(i) A person who violates Subsection (2)(a)(i) with respect to all other controlled
2982	2982	1467
2983	2983	substances not included in Subsection (2)(b)(i) or (ii), including a substance listed
2984	2984	1468
2985	2985	in Section 58-37-4.2, or marijuana, is guilty of a class B misdemeanor.
2986	2986	1469
2987	2987	[(i)] (ii) Upon a third conviction the person is guilty of a class A misdemeanor, if each
2988	2988	1470
2989	2989	prior offense was committed within seven years before the date of the offense
2990	2990	1471
2991	2991	upon which the current conviction is based.
2992	2992	1472
2993	2993	[(ii)] (iii) Upon a fourth or subsequent conviction the person is guilty of a third degree
2994	2994	1473
2995	2995	felony if each prior offense was committed within seven years before the date of
2996	2996	1474
2997	2997	the offense upon which the current conviction is based.
2998	2998	1475
2999	2999	(e) A person convicted of violating Subsection (2)(a)(i) while inside the exterior
3000	3000	1476
3001	3001	boundaries of property occupied by a correctional facility as defined in Section
3002	3002	1477
3003	3003	64-13-1 or a public jail or other place of confinement shall be sentenced to a penalty
3004	3004	1478
3005	3005	one degree greater than provided in Subsection (2)(b), and if the conviction is with
3006	3006	1479
3007	3007	respect to controlled substances as listed in:
3008	3008	1480
3009	3009	(i) Subsection (2)(b), the person may be sentenced to imprisonment for an
3010	3010	1481
3011	3011	indeterminate term as provided by law, and:
3012	3012	1482
3013	3013	(A) the court shall additionally sentence the person convicted to a term of one year
3014	3014	1483
3015	3015	to run consecutively and not concurrently; and
3016	3016	1484
3017	3017	(B) the court may additionally sentence the person convicted for an indeterminate
3018	3018	1485
3019	3019	term not to exceed five years to run consecutively and not concurrently; and
3020	3020	1486
3021	3021	(ii) Subsection (2)(d), the person may be sentenced to imprisonment for an
3022	3022	1487
3023	3023	indeterminate term as provided by law, and the court shall additionally sentence
3024	3024	1488
3025	3025	the person convicted to a term of six months to run consecutively and not
3026	3026	1489
3027	3027	concurrently.
3028	3028	1490
3029	3029	(f) A person convicted of violating Subsection (2)(a)(ii) or (iii) is:
3030	3030	1491
3031	3031	(i) on a first conviction, guilty of a class B misdemeanor;
3032	3032	1492
3033	3033	(ii) on a second conviction, guilty of a class A misdemeanor; and
3034	3034	- 44 - 02-21 16:04 H.B. 543
3035	3035	1493
3036	3036	(iii) on a third or subsequent conviction, guilty of a third degree felony.
3037	3037	1494
3038	3038	(g) The Administrative Office of the Courts shall report to the Division of Professional
3039	3039	1495
3040	3040	Licensing the name, case number, date of conviction, and if known, the date of birth
3041	3041	1496
3042	3042	of each person convicted of violating Subsection (2)(a).
3043	3043	1497
3044	3044	(3) Prohibited acts C -- Penalties:
3045	3045	1498
3046	3046	(a) It is unlawful for a person knowingly and intentionally:
3047	3047	1499
3048	3048	(i) to use in the course of the manufacture or distribution of a controlled substance a [
3049	3049	1500
3050	3050	license] federal Drug Enforcement Administration registration number or
3051	3051	1501
3052	3052	controlled substance certification which is fictitious, revoked, suspended, or
3053	3053	1502
3054	3054	issued to another person or, for the purpose of obtaining a controlled substance, to
3055	3055	1503
3056	3056	assume the title of, or represent oneself to be, a manufacturer, wholesaler,
3057	3057	1504
3058	3058	apothecary, physician, dentist, veterinarian, or other authorized person;
3059	3059	1505
3060	3060	(ii) to acquire or obtain possession of, to procure or attempt to procure the
3061	3061	1506
3062	3062	administration of, to obtain a prescription for, to prescribe or dispense to a person
3063	3063	1507
3064	3064	known to be attempting to acquire or obtain possession of, or to procure the
3065	3065	1508
3066	3066	administration of a controlled substance by misrepresentation or failure by the
3067	3067	1509
3068	3068	person to disclose receiving a controlled substance from another source, fraud,
3069	3069	1510
3070	3070	forgery, deception, subterfuge, alteration of a prescription or written order for a
3071	3071	1511
3072	3072	controlled substance, or the use of a false name or address;
3073	3073	1512
3074	3074	(iii) to make a false or forged prescription or written order for a controlled substance,
3075	3075	1513
3076	3076	or to utter the same, or to alter a prescription or written order issued or written
3077	3077	1514
3078	3078	under the terms of this chapter; or
3079	3079	1515
3080	3080	(iv) to make, distribute, or possess a punch, die, plate, stone, or other thing designed
3081	3081	1516
3082	3082	to print, imprint, or reproduce the trademark, trade name, or other identifying
3083	3083	1517
3084	3084	mark, imprint, or device of another or any likeness of any of the foregoing upon
3085	3085	1518
3086	3086	any drug or container or labeling so as to render a drug a counterfeit controlled
3087	3087	1519
3088	3088	substance.
3089	3089	1520
3090	3090	(b)(i) A first or second conviction under Subsection (3)(a)(i), (ii), or (iii) is a class A
3091	3091	1521
3092	3092	misdemeanor.
3093	3093	1522
3094	3094	(ii) A third or subsequent conviction under Subsection (3)(a)(i), (ii), or (iii) is a third
3095	3095	1523
3096	3096	degree felony.
3097	3097	1524
3098	3098	(c) A violation of Subsection (3)(a)(iv) is a third degree felony.
3099	3099	1525
3100	3100	(4) Prohibited acts D -- Penalties:
3101	3101	1526
3102	3102	(a) Notwithstanding other provisions of this section, a person not authorized under this
3103	3103	- 45 - H.B. 543 02-21 16:04
3104	3104	1527
3105	3105	chapter who commits any act that is unlawful under Subsection (1)(a) or Section
3106	3106	1528
3107	3107	58-37b-4 is upon conviction subject to the penalties and classifications under this
3108	3108	1529
3109	3109	Subsection (4) if the trier of fact finds the act is committed:
3110	3110	1530
3111	3111	(i) in a public or private elementary or secondary school or on the grounds of any of
3112	3112	1531
3113	3113	those schools during the hours of 6 a.m. through 10 p.m.;
3114	3114	1532
3115	3115	(ii) in a public or private vocational school or postsecondary institution or on the
3116	3116	1533
3117	3117	grounds of any of those schools or institutions during the hours of 6 a.m. through
3118	3118	1534
3119	3119	10 p.m.;
3120	3120	1535
3121	3121	(iii) in or on the grounds of a preschool or child-care facility during the preschool's or
3122	3122	1536
3123	3123	facility's hours of operation;
3124	3124	1537
3125	3125	(iv) in a public park, amusement park, arcade, or recreation center when the public or
3126	3126	1538
3127	3127	amusement park, arcade, or recreation center is open to the public;
3128	3128	1539
3129	3129	(v) in or on the grounds of a house of worship as defined in Section 76-10-501;
3130	3130	1540
3131	3131	(vi) in or on the grounds of a library when the library is open to the public;
3132	3132	1541
3133	3133	(vii) within an area that is within 100 feet of any structure, facility, or grounds
3134	3134	1542
3135	3135	included in Subsections (4)(a)(i) through (vi);
3136	3136	1543
3137	3137	(viii) in the presence of a person younger than 18 years old, regardless of where the
3138	3138	1544
3139	3139	act occurs; or
3140	3140	1545
3141	3141	(ix) for the purpose of facilitating, arranging, or causing the transport, delivery, or
3142	3142	1546
3143	3143	distribution of a substance in violation of this section to an inmate or on the
3144	3144	1547
3145	3145	grounds of a correctional facility as defined in Section 76-8-311.3.
3146	3146	1548
3147	3147	(b)(i) A person convicted under this Subsection (4) is guilty of a first degree felony
3148	3148	1549
3149	3149	and shall be imprisoned for a term of not less than five years if the penalty that
3150	3150	1550
3151	3151	would otherwise have been established but for this Subsection (4) would have
3152	3152	1551
3153	3153	been a first degree felony.
3154	3154	1552
3155	3155	(ii) Imposition or execution of the sentence may not be suspended, and the person is
3156	3156	1553
3157	3157	not eligible for probation.
3158	3158	1554
3159	3159	(c) If the classification that would otherwise have been established would have been less
3160	3160	1555
3161	3161	than a first degree felony but for this Subsection (4), a person convicted under this
3162	3162	1556
3163	3163	Subsection (4) is guilty of one degree more than the maximum penalty prescribed for
3164	3164	1557
3165	3165	that offense.
3166	3166	1558
3167	3167	(d)(i) If the violation is of Subsection (4)(a)(ix):
3168	3168	1559
3169	3169	(A) the person may be sentenced to imprisonment for an indeterminate term as
3170	3170	1560
3171	3171	provided by law, and the court shall additionally sentence the person convicted
3172	3172	- 46 - 02-21 16:04 H.B. 543
3173	3173	1561
3174	3174	for a term of one year to run consecutively and not concurrently; and
3175	3175	1562
3176	3176	(B) the court may additionally sentence the person convicted for an indeterminate
3177	3177	1563
3178	3178	term not to exceed five years to run consecutively and not concurrently; and
3179	3179	1564
3180	3180	(ii) the penalties under this Subsection (4)(d) apply also to a person who, acting with
3181	3181	1565
3182	3182	the mental state required for the commission of an offense, directly or indirectly
3183	3183	1566
3184	3184	solicits, requests, commands, coerces, encourages, or intentionally aids another
3185	3185	1567
3186	3186	person to commit a violation of Subsection (4)(a)(ix).
3187	3187	1568
3188	3188	(e) It is not a defense to a prosecution under this Subsection (4) that:
3189	3189	1569
3190	3190	(i) the actor mistakenly believed the individual to be 18 years old or older at the time
3191	3191	1570
3192	3192	of the offense or was unaware of the individual's true age; or
3193	3193	1571
3194	3194	(ii) the actor mistakenly believed that the location where the act occurred was not as
3195	3195	1572
3196	3196	described in Subsection (4)(a) or was unaware that the location where the act
3197	3197	1573
3198	3198	occurred was as described in Subsection (4)(a).
3199	3199	1574
3200	3200	(5) A violation of this chapter for which no penalty is specified is a class B misdemeanor.
3201	3201	1575
3202	3202	(6)(a) For purposes of penalty enhancement under Subsections (1) and (2), a plea of
3203	3203	1576
3204	3204	guilty or no contest to a violation or attempted violation of this section or a plea
3205	3205	1577
3206	3206	which is held in abeyance under Title 77, Chapter 2a, Pleas in Abeyance, is the
3207	3207	1578
3208	3208	equivalent of a conviction, even if the charge has been subsequently reduced or
3209	3209	1579
3210	3210	dismissed in accordance with the plea in abeyance agreement.
3211	3211	1580
3212	3212	(b) A prior conviction used for a penalty enhancement under Subsection (2) shall be a
3213	3213	1581
3214	3214	conviction that is:
3215	3215	1582
3216	3216	(i) from a separate criminal episode than the current charge; and
3217	3217	1583
3218	3218	(ii) from a conviction that is separate from any other conviction used to enhance the
3219	3219	1584
3220	3220	current charge.
3221	3221	1585
3222	3222	(7) A person may be charged and sentenced for a violation of this section, notwithstanding
3223	3223	1586
3224	3224	a charge and sentence for a violation of any other section of this chapter.
3225	3225	1587
3226	3226	(8)(a) A penalty imposed for violation of this section is in addition to, and not in lieu of,
3227	3227	1588
3228	3228	a civil or administrative penalty or sanction authorized by law.
3229	3229	1589
3230	3230	(b) When a violation of this chapter violates a federal law or the law of another state,
3231	3231	1590
3232	3232	conviction or acquittal under federal law or the law of another state for the same act
3233	3233	1591
3234	3234	is a bar to prosecution in this state.
3235	3235	1592
3236	3236	(9) In any prosecution for a violation of this chapter, evidence or proof that shows a person
3237	3237	1593
3238	3238	or persons produced, manufactured, possessed, distributed, or dispensed a controlled
3239	3239	1594
3240	3240	substance or substances, is prima facie evidence that the person or persons did so with
3241	3241	- 47 - H.B. 543 02-21 16:04
3242	3242	1595
3243	3243	knowledge of the character of the substance or substances.
3244	3244	1596
3245	3245	(10) This section does not prohibit a veterinarian, in good faith and in the course of the
3246	3246	1597
3247	3247	veterinarian's professional practice only and not for humans, from prescribing,
3248	3248	1598
3249	3249	dispensing, or administering controlled substances or from causing the substances to be
3250	3250	1599
3251	3251	administered by an assistant or orderly under the veterinarian's direction and supervision.
3252	3252	1600
3253	3253	(11) Civil or criminal liability may not be imposed under this section on:
3254	3254	1601
3255	3255	(a) a person registered under this chapter who manufactures, distributes, or possesses an
3256	3256	1602
3257	3257	imitation controlled substance for use as a placebo or investigational new drug by a
3258	3258	1603
3259	3259	registered practitioner in the ordinary course of professional practice or research;
3260	3260	1604
3261	3261	(b) a law enforcement officer acting in the course and legitimate scope of the officer's
3262	3262	1605
3263	3263	employment; or
3264	3264	1606
3265	3265	(c) a healthcare facility, substance use harm reduction services program, or drug
3266	3266	1607
3267	3267	addiction treatment facility that temporarily possesses a controlled or counterfeit
3268	3268	1608
3269	3269	substance to conduct a test or analysis on the controlled or counterfeit substance to
3270	3270	1609
3271	3271	identify or analyze the strength, effectiveness, or purity of the substance for a public
3272	3272	1610
3273	3273	health or safety reason.
3274	3274	1611
3275	3275	(12)(a) Civil or criminal liability may not be imposed under this section on any Indian,
3276	3276	1612
3277	3277	as defined in Section 58-37-2, who uses, possesses, or transports peyote for bona fide
3278	3278	1613
3279	3279	traditional ceremonial purposes in connection with the practice of a traditional Indian
3280	3280	1614
3281	3281	religion as defined in Section 58-37-2.
3282	3282	1615
3283	3283	(b) In a prosecution alleging violation of this section regarding peyote as defined in
3284	3284	1616
3285	3285	Section 58-37-4, it is an affirmative defense that the peyote was used, possessed, or
3286	3286	1617
3287	3287	transported by an Indian for bona fide traditional ceremonial purposes in connection
3288	3288	1618
3289	3289	with the practice of a traditional Indian religion.
3290	3290	1619
3291	3291	(c)(i) The defendant shall provide written notice of intent to claim an affirmative
3292	3292	1620
3293	3293	defense under this Subsection (12) as soon as practicable, but not later than 10
3294	3294	1621
3295	3295	days before trial.
3296	3296	1622
3297	3297	(ii) The notice shall include the specific claims of the affirmative defense.
3298	3298	1623
3299	3299	(iii) The court may waive the notice requirement in the interest of justice for good
3300	3300	1624
3301	3301	cause shown, if the prosecutor is not unfairly prejudiced by the lack of timely
3302	3302	1625
3303	3303	notice.
3304	3304	1626
3305	3305	(d) The defendant shall establish the affirmative defense under this Subsection (12) by a
3306	3306	1627
3307	3307	preponderance of the evidence. If the defense is established, it is a complete defense
3308	3308	1628
3309	3309	to the charges.
3310	3310	- 48 - 02-21 16:04 H.B. 543
3311	3311	1629
3312	3312	(13)(a) It is an affirmative defense that the person produced, possessed, or administered
3313	3313	1630
3314	3314	a controlled substance listed in Section 58-37-4.2 if the person was:
3315	3315	1631
3316	3316	(i) engaged in medical research; and
3317	3317	1632
3318	3318	(ii) a holder of a valid [license to possess controlled substances under Section 58-37-6]
3319	3319	1633
3320	3320	federal Drug Enforcement Administration registration.
3321	3321	1634
3322	3322	(b) It is not a defense under Subsection (13)(a) that the person prescribed or dispensed a
3323	3323	1635
3324	3324	controlled substance listed in Section 58-37-4.2.
3325	3325	1636
3326	3326	(14) It is an affirmative defense that the person possessed, in the person's body, a controlled
3327	3327	1637
3328	3328	substance listed in Section 58-37-4.2 if:
3329	3329	1638
3330	3330	(a) the person was the subject of medical research conducted by a holder of a valid [
3331	3331	1639
3332	3332	license to possess controlled substances under Section 58-37-6] federal Drug
3333	3333	1640
3334	3334	Enforcement Administration registration; and
3335	3335	1641
3336	3336	(b) the substance was administered to the person by the medical researcher.
3337	3337	1642
3338	3338	(15) The application of any increase in penalty under this section to a violation of
3339	3339	1643
3340	3340	Subsection (2)(a)(i) may not result in any greater penalty than a second degree felony.
3341	3341	1644
3342	3342	This Subsection (15) takes precedence over any conflicting provision of this section.
3343	3343	1645
3344	3344	(16)(a) It is an affirmative defense to an allegation of the commission of an offense
3345	3345	1646
3346	3346	listed in Subsection (16)(b) that the person or bystander:
3347	3347	1647
3348	3348	(i) reasonably believes that the person or another person is experiencing an overdose
3349	3349	1648
3350	3350	event due to the ingestion, injection, inhalation, or other introduction into the
3351	3351	1649
3352	3352	human body of a controlled substance or other substance;
3353	3353	1650
3354	3354	(ii) reports, or assists a person who reports, in good faith the overdose event to a
3355	3355	1651
3356	3356	medical provider, an emergency medical service provider as defined in Section
3357	3357	1652
3358	3358	53-2d-101, a law enforcement officer, a 911 emergency call system, or an
3359	3359	1653
3360	3360	emergency dispatch system, or the person is the subject of a report made under
3361	3361	1654
3362	3362	this Subsection (16);
3363	3363	1655
3364	3364	(iii) provides in the report under Subsection (16)(a)(ii) a functional description of the
3365	3365	1656
3366	3366	actual location of the overdose event that facilitates responding to the person
3367	3367	1657
3368	3368	experiencing the overdose event;
3369	3369	1658
3370	3370	(iv) remains at the location of the person experiencing the overdose event until a
3371	3371	1659
3372	3372	responding law enforcement officer or emergency medical service provider
3373	3373	1660
3374	3374	arrives, or remains at the medical care facility where the person experiencing an
3375	3375	1661
3376	3376	overdose event is located until a responding law enforcement officer arrives;
3377	3377	1662
3378	3378	(v) cooperates with the responding medical provider, emergency medical service
3379	3379	- 49 - H.B. 543 02-21 16:04
3380	3380	1663
3381	3381	provider, and law enforcement officer, including providing information regarding
3382	3382	1664
3383	3383	the person experiencing the overdose event and any substances the person may
3384	3384	1665
3385	3385	have injected, inhaled, or otherwise introduced into the person's body; and
3386	3386	1666
3387	3387	(vi) is alleged to have committed the offense in the same course of events from which
3388	3388	1667
3389	3389	the reported overdose arose.
3390	3390	1668
3391	3391	(b) The offenses referred to in Subsection (16)(a) are:
3392	3392	1669
3393	3393	(i) the possession or use of less than 16 ounces of marijuana;
3394	3394	1670
3395	3395	(ii) the possession or use of a scheduled or listed controlled substance other than
3396	3396	1671
3397	3397	marijuana; and
3398	3398	1672
3399	3399	(iii) any violation of Chapter 37a, Utah Drug Paraphernalia Act, or Chapter 37b,
3400	3400	1673
3401	3401	Imitation Controlled Substances Act.
3402	3402	1674
3403	3403	(c) As used in this Subsection (16) and in Section 76-3-203.11, "good faith" does not
3404	3404	1675
3405	3405	include seeking medical assistance under this section during the course of a law
3406	3406	1676
3407	3407	enforcement agency's execution of a search warrant, execution of an arrest warrant,
3408	3408	1677
3409	3409	or other lawful search.
3410	3410	1678
3411	3411	(17) If any provision of this chapter, or the application of any provision to any person or
3412	3412	1679
3413	3413	circumstances, is held invalid, the remainder of this chapter shall be given effect without
3414	3414	1680
3415	3415	the invalid provision or application.
3416	3416	1681
3417	3417	(18) A legislative body of a political subdivision may not enact an ordinance that is less
3418	3418	1682
3419	3419	restrictive than any provision of this chapter.
3420	3420	1683
3421	3421	(19) If a minor who is under 18 years old is found by a court to have violated this section or
3422	3422	1684
3423	3423	Subsection 76-5-102.1(2)(b) or 76-5-207(2)(b), the court may order the minor to
3424	3424	1685
3425	3425	complete:
3426	3426	1686
3427	3427	(a) a screening as defined in Section 41-6a-501;
3428	3428	1687
3429	3429	(b) an assessment as defined in Section 41-6a-501 if the screening indicates an
3430	3430	1688
3431	3431	assessment to be appropriate; and
3432	3432	1689
3433	3433	(c) an educational series as defined in Section 41-6a-501 or substance use disorder
3434	3434	1690
3435	3435	treatment as indicated by an assessment.
3436	3436	1691
3437	3437	Section 8. Section 58-37-10 is amended to read:
3438	3438	1692
3439	3439	58-37-10 (Effective 07/01/25). Search warrants -- Administrative inspection
3440	3440	1693
3441	3441	warrants -- Inspections and seizures of property without warrant.
3442	3442	1694
3443	3443	(1) Search warrants relating to offenses involving controlled substances may be authorized
3444	3444	1695
3445	3445	pursuant to the Utah Rules of Criminal Procedure.
3446	3446	1696
3447	3447	(2) Issuance and execution of administrative inspection warrants shall be as follows:
3448	3448	- 50 - 02-21 16:04 H.B. 543
3449	3449	1697
3450	3450	(a) Any judge or magistrate of this state within his jurisdiction upon proper oath or
3451	3451	1698
3452	3452	affirmation showing probable cause, may issue warrants for the purpose of
3453	3453	1699
3454	3454	conducting administrative inspections authorized by this act or regulations thereunder
3455	3455	1700
3456	3456	and seizures of property appropriate to such inspections. Probable cause for purposes
3457	3457	1701
3458	3458	of this act exists upon showing a valid public interest in the effective enforcement of
3459	3459	1702
3460	3460	the act or rules promulgated thereunder sufficient to justify administrative inspection
3461	3461	1703
3462	3462	of the area, premises, building, or conveyance in the circumstances specified in the
3463	3463	1704
3464	3464	application for the warrant.
3465	3465	1705
3466	3466	(b) A warrant shall issue only upon an affidavit of an officer or employee duly
3467	3467	1706
3468	3468	designated and having knowledge of the facts alleged sworn to before a judge or
3469	3469	1707
3470	3470	magistrate which establish the grounds for issuing the warrant. If the judge or
3471	3471	1708
3472	3472	magistrate is satisfied that grounds for the application exist or that there is probable
3473	3473	1709
3474	3474	cause to believe they exist, he shall issue a warrant identifying the area, premises,
3475	3475	1710
3476	3476	building, or conveyance to be inspected, the purpose of the inspection, and if
3477	3477	1711
3478	3478	appropriate, the type of property to be inspected, if any. The warrant shall:
3479	3479	1712
3480	3480	(i) state the grounds for its issuance and the name of each person whose affidavit has
3481	3481	1713
3482	3482	been taken to support it;
3483	3483	1714
3484	3484	(ii) be directed to a person authorized by Section 58-37-9 of this act to execute it;
3485	3485	1715
3486	3486	(iii) command the person to whom it is directed to inspect the area, premises,
3487	3487	1716
3488	3488	building, or conveyance identified for the purpose specified and if appropriate,
3489	3489	1717
3490	3490	direct the seizure of the property specified;
3491	3491	1718
3492	3492	(iv) identify the item or types of property to be seized, if any; and
3493	3493	1719
3494	3494	(v) direct that it be served during normal business hours and designate the judge or
3495	3495	1720
3496	3496	magistrate to whom it shall be returned.
3497	3497	1721
3498	3498	(c) A warrant issued pursuant to this section must be executed and returned within 10
3499	3499	1722
3500	3500	days after its date unless, upon a showing of a need for additional time, the court
3501	3501	1723
3502	3502	instructs otherwise in the warrant. If property is seized pursuant to a warrant, the
3503	3503	1724
3504	3504	person executing the warrant shall give to the person from whom or from whose
3505	3505	1725
3506	3506	premises the property was taken a copy of the warrant and a receipt for the property
3507	3507	1726
3508	3508	taken or leave the copy and receipt at the place where the property was taken. Return
3509	3509	1727
3510	3510	of the warrant shall be made promptly and be accompanied by a written inventory of
3511	3511	1728
3512	3512	any property taken. The inventory shall be made in the presence of the person
3513	3513	1729
3514	3514	executing the warrant and of the person from whose possession or premises the
3515	3515	1730
3516	3516	property was taken, if they are present, or in the presence of at least one credible
3517	3517	- 51 - H.B. 543 02-21 16:04
3518	3518	1731
3519	3519	person other than the person executing the warrant. A copy of the inventory shall be
3520	3520	1732
3521	3521	delivered to the person from whom or from whose premises the property was taken
3522	3522	1733
3523	3523	and to the applicant for the warrant.
3524	3524	1734
3525	3525	(d) The judge or magistrate who issued the warrant under this section shall attach a copy
3526	3526	1735
3527	3527	of the return and all other papers to the warrant and file them with the court.
3528	3528	1736
3529	3529	(3) The department is authorized to make administrative inspections of controlled premises
3530	3530	1737
3531	3531	in accordance with the following provisions:
3532	3532	1738
3533	3533	(a) For purposes of this section only, "controlled premises" means:
3534	3534	1739
3535	3535	(i) [Places] places where persons [licensed or exempted from licensing requirements
3536	3536	1740
3537	3537	under this act ]are required to keep records[.] under this act; and
3538	3538	1741
3539	3539	(ii) [Places] places including factories, warehouses, establishments, and conveyances
3540	3540	1742
3541	3541	where persons [licensed or exempted from licensing requirements ]are permitted
3542	3542	1743
3543	3543	to possess, manufacture, compound, process, sell, deliver, or otherwise dispose of
3544	3544	1744
3545	3545	any controlled substance under this act.
3546	3546	1745
3547	3547	(b) When authorized by an administrative inspection warrant a law enforcement officer
3548	3548	1746
3549	3549	or employee designated in Section 58-37-9, upon presenting the warrant and
3550	3550	1747
3551	3551	appropriate credentials to the owner, operator, or agent in charge, has the right to
3552	3552	1748
3553	3553	enter controlled premises for the purpose of conducting an administrative inspection.
3554	3554	1749
3555	3555	(c) When authorized by an administrative inspection warrant, a law enforcement officer
3556	3556	1750
3557	3557	or employee designated in Section 58-37-9 has the right:
3558	3558	1751
3559	3559	(i) [To] to inspect and copy records required by this chapter[.] ;
3560	3560	1752
3561	3561	(ii) [To] to inspect within reasonable limits and a reasonable manner, the controlled
3562	3562	1753
3563	3563	premises and all pertinent equipment, finished and unfinished material, containers,
3564	3564	1754
3565	3565	and labeling found, and except as provided in Subsection (3)(e), all other things
3566	3566	1755
3567	3567	including records, files, papers, processes, controls, and facilities subject to
3568	3568	1756
3569	3569	regulation and control by this chapter or by rules promulgated by the department[.] ;
3570	3570	1757
3571	3571	and
3572	3572	1758
3573	3573	(iii) [To] to inventory and take stock of any controlled substance and obtain samples
3574	3574	1759
3575	3575	of any substance.
3576	3576	1760
3577	3577	(d) This section shall not be construed to prevent the inspection of books and records
3578	3578	1761
3579	3579	without a warrant pursuant to an administrative subpoena issued by a court or the
3580	3580	1762
3581	3581	department nor shall it be construed to prevent entries and administrative inspections
3582	3582	1763
3583	3583	including seizures of property without a warrant:
3584	3584	1764
3585	3585	(i) with the consent of the owner, operator, or agent in charge of the controlled
3586	3586	- 52 - 02-21 16:04 H.B. 543
3587	3587	1765
3588	3588	premises;
3589	3589	1766
3590	3590	(ii) in situations presenting imminent danger to health or safety;
3591	3591	1767
3592	3592	(iii) in situations involving inspection of conveyances where there is reasonable cause
3593	3593	1768
3594	3594	to believe that the mobility of the conveyance makes it impracticable to obtain a
3595	3595	1769
3596	3596	warrant;
3597	3597	1770
3598	3598	(iv) in any other exceptional or emergency circumstance where time or opportunity to
3599	3599	1771
3600	3600	apply for a warrant is lacking; and
3601	3601	1772
3602	3602	(v) in all other situations where a warrant is not constitutionally required.
3603	3603	1773
3604	3604	(e) No inspection authorized by this section shall extend to financial data, sales data,
3605	3605	1774
3606	3606	other than shipment data, or pricing data unless the owner, operator, or agent in
3607	3607	1775
3608	3608	charge of the controlled premises consents in writing.
3609	3609	1776
3610	3610	Section 9. Section 58-37-15 is amended to read:
3611	3611	1777
3612	3612	58-37-15 (Effective 07/01/25). Burden of proof in proceedings on violations --
3613	3613	1778
3614	3614	Enforcement officers exempt from liability.
3615	3615	1779
3616	3616	(1) It is not necessary for the state to negate any exemption or exception set forth in this act
3617	3617	1780
3618	3618	in any complaint, information, indictment or other pleading or trial, hearing, or other
3619	3619	1781
3620	3620	proceeding under this act, and the burden of proof of any exemption or exception is
3621	3621	1782
3622	3622	upon the person claiming its benefit.
3623	3623	1783
3624	3624	(2) In absence of proof that a person is the duly authorized holder of an appropriate [
3625	3625	1784
3626	3626	license, ]registration, certification, order form, or prescription issued under this act, [he]
3627	3627	1785
3628	3628	that person shall be presumed not to be the holder of a [license, ]registration,
3629	3629	1786
3630	3630	certification, order form, or prescription, and the burden of proof is upon [him] that
3631	3631	1787
3632	3632	person to rebut the presumption.
3633	3633	1788
3634	3634	(3) No liability shall be imposed upon any duly authorized state or federal officer engaged
3635	3635	1789
3636	3636	in the enforcement of this act who is engaged in the enforcement of any law, municipal
3637	3637	1790
3638	3638	ordinance, or regulation relating to controlled substances.
3639	3639	1791
3640	3640	Section 10. Section 58-37-19 is amended to read:
3641	3641	1792
3642	3642	58-37-19 (Effective 07/01/25). Opiate prescription consultation -- Prescription
3643	3643	1793
3644	3644	for opiate antagonist required.
3645	3645	1794
3646	3646	(1) As used in this section:
3647	3647	1795
3648	3648	(a) "Initial opiate prescription" means a prescription for an opiate to a patient who:
3649	3649	1796
3650	3650	(i) has never previously been issued a prescription for an opiate; or
3651	3651	1797
3652	3652	(ii) was previously issued a prescription for an opiate, but the date on which the
3653	3653	1798
3654	3654	current prescription is being issued is more than one year after the date on which
3655	3655	- 53 - H.B. 543 02-21 16:04
3656	3656	1799
3657	3657	an opiate was previously prescribed or administered to the patient.
3658	3658	1800
3659	3659	(b) "Opiate antagonist" means the same as that term is defined in Section 26B-4-501.
3660	3660	1801
3661	3661	(c) "Prescriber" means an individual authorized to prescribe a controlled substance under
3662	3662	1802
3663	3663	this chapter.
3664	3664	1803
3665	3665	(2) Except as provided in Subsection (3), a prescriber may not issue an initial opiate
3666	3666	1804
3667	3667	prescription without discussing with the patient, or the patient's parent or guardian if the
3668	3668	1805
3669	3669	patient is under 18 years old and is not an emancipated minor:
3670	3670	1806
3671	3671	(a) the risks of addiction and overdose associated with opiate drugs;
3672	3672	1807
3673	3673	(b) the dangers of taking opiates with alcohol, benzodiazepines, and other central
3674	3674	1808
3675	3675	nervous system depressants;
3676	3676	1809
3677	3677	(c) the reasons why the prescription is necessary;
3678	3678	1810
3679	3679	(d) alternative treatments that may be available; and
3680	3680	1811
3681	3681	(e) other risks associated with the use of the drugs being prescribed.
3682	3682	1812
3683	3683	(3) Subsection (2) does not apply to a prescription for:
3684	3684	1813
3685	3685	(a) a patient who is currently in active treatment for cancer;
3686	3686	1814
3687	3687	(b) a patient who is receiving hospice care from a licensed hospice as defined in Section
3688	3688	1815
3689	3689	26B-2-201; or
3690	3690	1816
3691	3691	(c) a medication that is being prescribed to a patient for the treatment of the patient's
3692	3692	1817
3693	3693	substance abuse or opiate dependence.
3694	3694	1818
3695	3695	(4)(a) Beginning January 1, 2024, a prescriber shall offer to prescribe or dispense an
3696	3696	1819
3697	3697	opiate antagonist to a patient if the patient receives an initial opiate prescription for:
3698	3698	1820
3699	3699	(i) 50 morphine milligram equivalents or more per day, calculated in accordance with
3700	3700	1821
3701	3701	guidelines developed by the United States Centers for Disease Control and
3702	3702	1822
3703	3703	Prevention; or
3704	3704	1823
3705	3705	(ii) any opiate if the practitioner is also prescribing a benzodiazepine to the patient.
3706	3706	1824
3707	3707	(b) Subsection (4)(a) does not apply if the initial opiate prescription:
3708	3708	1825
3709	3709	(i) is administered directly to an ultimate user by a [licensed] certified practitioner; or
3710	3710	1826
3711	3711	(ii) is for a three-day supply or less.
3712	3712	1827
3713	3713	(c) This Subsection (4) does not require a patient to purchase or obtain an opiate
3714	3714	1828
3715	3715	antagonist as a condition of receiving the patient's initial opiate prescription.
3716	3716	1829
3717	3717	Section 11. Section 58-37-22 is amended to read:
3718	3718	1830
3719	3719	58-37-22 (Effective 07/01/25). Electronic prescriptions for controlled substances.
3720	3720	1831
3721	3721	(1) Beginning January 1, 2022, each prescription issued for a controlled substance shall be
3722	3722	1832
3723	3723	transmitted electronically as an electronic prescription unless the prescription is:
3724	3724	- 54 - 02-21 16:04 H.B. 543
3725	3725	1833
3726	3726	(a) for a patient residing in an assisted living facility as that term is defined in Section
3727	3727	1834
3728	3728	26B-2-201, a long-term care facility as that term is defined in Section 58-31b-102, or
3729	3729	1835
3730	3730	a correctional facility as that term is defined in Section 64-13-1;
3731	3731	1836
3732	3732	(b) issued by a veterinarian licensed under Chapter 28, Veterinary Practice Act;
3733	3733	1837
3734	3734	(c) dispensed by a Department of Veterans Affairs pharmacy;
3735	3735	1838
3736	3736	(d) issued during a temporary technical or electronic failure at the practitioner's or
3737	3737	1839
3738	3738	pharmacy's location; or
3739	3739	1840
3740	3740	(e) issued in an emergency situation.
3741	3741	1841
3742	3742	(2) The division, in collaboration with the appropriate boards that govern the licensure of [
3743	3743	1842
3744	3744	the licensees who are authorized by the division to prescribe or to dispense controlled
3745	3745	1843
3746	3746	substances] certified practitioners, shall make rules in accordance with Title 63G,
3747	3747	1844
3748	3748	Chapter 3, Utah Administrative Rulemaking Act, to:
3749	3749	1845
3750	3750	(a) require that controlled substances prescribed or dispensed under Subsection (1)(d)
3751	3751	1846
3752	3752	indicate on the prescription that the prescribing practitioner or the pharmacy is
3753	3753	1847
3754	3754	experiencing a technical difficulty or an electronic failure;
3755	3755	1848
3756	3756	(b) define an emergency situation for purposes of Subsection (1)(e);
3757	3757	1849
3758	3758	(c) establish additional exemptions to the electronic prescription requirements
3759	3759	1850
3760	3760	established in this section;
3761	3761	1851
3762	3762	(d) establish guidelines under which a prescribing practitioner or a pharmacy may obtain
3763	3763	1852
3764	3764	an extension of up to two additional years to comply with Subsection (1);
3765	3765	1853
3766	3766	(e) establish a protocol to follow if the pharmacy that receives the electronic prescription
3767	3767	1854
3768	3768	is not able to fill the prescription; and
3769	3769	1855
3770	3770	(f) establish requirements that comply with federal laws and regulations for software
3771	3771	1856
3772	3772	used to issue and dispense electronic prescriptions.
3773	3773	1857
3774	3774	(3) Beginning July 1, 2024, a pharmacy software program for receiving an electronic
3775	3775	1858
3776	3776	prescription for a controlled substance shall be capable of electronically transferring a
3777	3777	1859
3778	3778	prescription to a different pharmacy:
3779	3779	1860
3780	3780	(a) upon the request of the patient or the practitioner;
3781	3781	1861
3782	3782	(b) with the approval of a pharmacist at the originating pharmacy; and
3783	3783	1862
3784	3784	(c) if the prescription is unfilled.
3785	3785	1863
3786	3786	Section 12. Section 58-37b-2 is amended to read:
3787	3787	1864
3788	3788	58-37b-2 (Effective 07/01/25). Definitions.
3789	3789	1865
3790	3790	As used in this chapter:
3791	3791	1866
3792	3792	(1) "Controlled substance" has the same meaning as provided in Section 58-37-2.
3793	3793	- 55 - H.B. 543 02-21 16:04
3794	3794	1867
3795	3795	(2) "Distribute" means the actual, constructive, or attempted sale, transfer, delivery, or
3796	3796	1868
3797	3797	dispensing to another of an imitation controlled substance.
3798	3798	1869
3799	3799	(3) "Imitation controlled substance" means a substance designed or packaged to
3800	3800	1870
3801	3801	substantially resemble any legally or illegally manufactured controlled substance, but
3802	3802	1871
3803	3803	that is not:
3804	3804	1872
3805	3805	(a) a controlled substance; or
3806	3806	1873
3807	3807	(b) represented to be any legally or illegally manufactured controlled substance under
3808	3808	1874
3809	3809	Subsection [58-37-2(1)(i)(ii)] 58-37-2(1)(k)(ii).
3810	3810	1875
3811	3811	(4) "Manufacture" means the production, preparation, compounding, processing,
3812	3812	1876
3813	3813	encapsulating, tableting, packaging or repackaging, labeling or relabeling, of an
3814	3814	1877
3815	3815	imitation controlled substance.
3816	3816	1878
3817	3817	Section 13. Section 58-37f-201 is amended to read:
3818	3818	1879
3819	3819	58-37f-201 (Effective 07/01/25). Controlled substance database -- Creation --
3820	3820	1880
3821	3821	Purpose.
3822	3822	1881
3823	3823	(1) There is created within the division a controlled substance database.
3824	3824	1882
3825	3825	(2) The division shall administer and direct the functioning of the database in accordance
3826	3826	1883
3827	3827	with this chapter.
3828	3828	1884
3829	3829	(3) The division may, under state procurement laws, contract with another state agency or a
3830	3830	1885
3831	3831	private entity to establish, operate, or maintain the database.
3832	3832	1886
3833	3833	(4) The division shall, in collaboration with the board, determine whether to operate the
3834	3834	1887
3835	3835	database within the division or contract with another entity to operate the database,
3836	3836	1888
3837	3837	based on an analysis of costs and benefits.
3838	3838	1889
3839	3839	(5) The purpose of the database is to contain:
3840	3840	1890
3841	3841	(a) the data described in Section 58-37f-203 regarding prescriptions for dispensed
3842	3842	1891
3843	3843	controlled substances;
3844	3844	1892
3845	3845	(b) data reported to the division under Section 26B-2-225 regarding poisoning or
3846	3846	1893
3847	3847	overdose;
3848	3848	1894
3849	3849	(c) data reported to the division under Subsection 41-6a-502(5) or 41-6a-502.5(5)(b)
3850	3850	1895
3851	3851	regarding convictions for driving under the influence of a prescribed controlled
3852	3852	1896
3853	3853	substance or impaired driving;[ and]
3854	3854	1897
3855	3855	(d) data reported to the division under Subsection 58-37-8(1)(e) or 58-37-8(2)(g)
3856	3856	1898
3857	3857	regarding certain violations of Chapter 37, Utah Controlled Substances Act[.] ; and
3858	3858	1899
3859	3859	(e) the data described in Subsection 58-37-6(2)(b).
3860	3860	1900
3861	3861	(6) The division shall maintain the database in an electronic file or by other means
3862	3862	- 56 - 02-21 16:04 H.B. 543
3863	3863	1901
3864	3864	established by the division to facilitate use of the database for identification of:
3865	3865	1902
3866	3866	(a) prescribing practices and patterns of prescribing and dispensing controlled
3867	3867	1903
3868	3868	substances;
3869	3869	1904
3870	3870	(b) practitioners prescribing controlled substances in an unprofessional or unlawful
3871	3871	1905
3872	3872	manner;
3873	3873	1906
3874	3874	(c) individuals receiving prescriptions for controlled substances from licensed
3875	3875	1907
3876	3876	practitioners, and who subsequently obtain dispensed controlled substances from a
3877	3877	1908
3878	3878	drug outlet in quantities or with a frequency inconsistent with generally recognized
3879	3879	1909
3880	3880	standards of dosage for that controlled substance;
3881	3881	1910
3882	3882	(d) individuals presenting forged or otherwise false or altered prescriptions for
3883	3883	1911
3884	3884	controlled substances to a pharmacy;
3885	3885	1912
3886	3886	(e) individuals admitted to a general acute hospital for poisoning or overdose involving a
3887	3887	1913
3888	3888	prescribed controlled substance; and
3889	3889	1914
3890	3890	(f) individuals convicted for:
3891	3891	1915
3892	3892	(i) driving under the influence of a prescribed controlled substance that renders the
3893	3893	1916
3894	3894	individual incapable of safely operating a vehicle;
3895	3895	1917
3896	3896	(ii) driving while impaired, in whole or in part, by a prescribed controlled substance;
3897	3897	1918
3898	3898	or
3899	3899	1919
3900	3900	(iii) certain violations of Chapter 37, Utah Controlled Substances Act.
3901	3901	1920
3902	3902	Section 14. Section 58-37f-303 is amended to read:
3903	3903	1921
3904	3904	58-37f-303 (Effective 07/01/25). Access to opioid prescription information via an
3905	3905	1922
3906	3906	electronic data system.
3907	3907	1923
3908	3908	(1) As used in this section:
3909	3909	1924
3910	3910	(a) "Dispense" means the same as that term is defined in Section 58-17b-102.
3911	3911	1925
3912	3912	(b) "EDS user":
3913	3913	1926
3914	3914	(i) means:
3915	3915	1927
3916	3916	(A) a prescriber;
3917	3917	1928
3918	3918	(B) a pharmacist;
3919	3919	1929
3920	3920	(C) a pharmacy intern;
3921	3921	1930
3922	3922	(D) a pharmacy technician; or
3923	3923	1931
3924	3924	(E) an individual granted access to the database under Subsection 58-37f-301(3)(c);
3925	3925	1932
3926	3926	and
3927	3927	1933
3928	3928	(ii) does not mean an individual whose access to the database has been revoked by
3929	3929	1934
3930	3930	the division pursuant to Subsection 58-37f-301(5)(c).
3931	3931	- 57 - H.B. 543 02-21 16:04
3932	3932	1935
3933	3933	(c) "Electronic data system" means a software product or an electronic service used by:
3934	3934	1936
3935	3935	(i) a prescriber to manage electronic health records; or
3936	3936	1937
3937	3937	(ii) a pharmacist, pharmacy intern, or pharmacy technician working under the general
3938	3938	1938
3939	3939	supervision of a licensed pharmacist, for the purpose of:
3940	3940	1939
3941	3941	(A) managing the dispensing of prescription drugs; or
3942	3942	1940
3943	3943	(B) providing pharmaceutical care as defined in Section 58-17b-102 to a patient.
3944	3944	1941
3945	3945	(d) "Opioid" means any substance listed in Subsection 58-37-4(2)(b)(i) or (2)(b)(ii).
3946	3946	1942
3947	3947	(e) "Pharmacist" means the same as that term is defined in Section 58-17b-102.
3948	3948	1943
3949	3949	(f) "Prescriber" means a [practitioner, as that term is defined in Section 58-37-2, who is
3950	3950	1944
3951	3951	licensed under Section 58-37-6 to prescribe an opioid] certified practitioner as that
3952	3952	1945
3953	3953	term is defined in Section 58-37-2.
3954	3954	1946
3955	3955	(g) "Prescription drug" means the same as that term is defined in Section 58-17b-102.
3956	3956	1947
3957	3957	(2) Subject to Subsections (3) through (6), no later than January 1, 2017, the division shall
3958	3958	1948
3959	3959	make opioid prescription information in the database available to an EDS user via the
3960	3960	1949
3961	3961	user's electronic data system.
3962	3962	1950
3963	3963	(3) An electronic data system may be used to make opioid prescription information in the
3964	3964	1951
3965	3965	database available to an EDS user only if the electronic data system complies with rules
3966	3966	1952
3967	3967	established by the division under Subsection (4).
3968	3968	1953
3969	3969	(4)(a) The division shall make rules, in accordance with Title 63G, Chapter 3, Utah
3970	3970	1954
3971	3971	Administrative Rulemaking Act, specifying:
3972	3972	1955
3973	3973	(i) an electronic data system's:
3974	3974	1956
3975	3975	(A) allowable access to and use of opioid prescription information in the database;
3976	3976	1957
3977	3977	and
3978	3978	1958
3979	3979	(B) minimum actions that must be taken to ensure that opioid prescription
3980	3980	1959
3981	3981	information accessed from the database is protected from inappropriate
3982	3982	1960
3983	3983	disclosure or use; and
3984	3984	1961
3985	3985	(ii) an EDS user's:
3986	3986	1962
3987	3987	(A) allowable access to opioid prescription information in the database via an
3988	3988	1963
3989	3989	electronic data system; and
3990	3990	1964
3991	3991	(B) allowable use of the information.
3992	3992	1965
3993	3993	(b) The rules shall establish:
3994	3994	1966
3995	3995	(i) minimum user identification requirements that in substance are the same as the
3996	3996	1967
3997	3997	database identification requirements in Section 58-37f-301;
3998	3998	1968
3999	3999	(ii) user access restrictions that in substance are the same as the database
4000	4000	- 58 - 02-21 16:04 H.B. 543
4001	4001	1969
4002	4002	identification requirements in Section 58-37f-301; and
4003	4003	1970
4004	4004	(iii) any other requirements necessary to ensure that in substance the provisions of
4005	4005	1971
4006	4006	Sections 58-37f-301 and 58-37f-302 apply to opioid prescription information in
4007	4007	1972
4008	4008	the database that has been made available to an EDS user via an electronic data
4009	4009	1973
4010	4010	system.
4011	4011	1974
4012	4012	(5) The division may not make opioid prescription information in the database available to
4013	4013	1975
4014	4014	an EDS user via the user's electronic data system if:
4015	4015	1976
4016	4016	(a) the electronic data system does not comply with the rules established by the division
4017	4017	1977
4018	4018	under Subsection (4); or
4019	4019	1978
4020	4020	(b) the EDS user does not comply with the rules established by the division under
4021	4021	1979
4022	4022	Subsection (4).
4023	4023	1980
4024	4024	(6)(a) The division shall periodically audit the use of opioid prescription information
4025	4025	1981
4026	4026	made available to an EDS user via the user's electronic data system.
4027	4027	1982
4028	4028	(b) The audit shall review compliance by:
4029	4029	1983
4030	4030	(i) the electronic data system with rules established by the division under Subsection
4031	4031	1984
4032	4032	(4); and
4033	4033	1985
4034	4034	(ii) the EDS user with rules established by the division under Subsection (4).
4035	4035	1986
4036	4036	(c)(i) If the division determines by audit or other means that an electronic data system
4037	4037	1987
4038	4038	is not in compliance with rules established by the division under Subsection (4),
4039	4039	1988
4040	4040	the division shall immediately suspend or revoke the electronic data system's
4041	4041	1989
4042	4042	access to opioid prescription information in the database.
4043	4043	1990
4044	4044	(ii) If the division determines by audit or other means that an EDS user is not in
4045	4045	1991
4046	4046	compliance with rules established by the division under Subsection (4), the
4047	4047	1992
4048	4048	division shall immediately suspend or revoke the EDS user's access to opioid
4049	4049	1993
4050	4050	prescription information in the database via an electronic data system.
4051	4051	1994
4052	4052	(iii) If the division suspends or revokes access to opioid prescription information in
4053	4053	1995
4054	4054	the database under Subsection (6)(c)(i) or (6)(c)(ii), the division shall also take
4055	4055	1996
4056	4056	any other appropriate corrective or disciplinary action authorized by this chapter
4057	4057	1997
4058	4058	or title.
4059	4059	1998
4060	4060	Section 15. Section 58-37f-304 is amended to read:
4061	4061	1999
4062	4062	58-37f-304 (Effective 07/01/25). Database utilization.
4063	4063	2000
4064	4064	(1) As used in this section:
4065	4065	2001
4066	4066	(a) "Dispenser" means a licensed pharmacist, as described in Section 58-17b-303, the
4067	4067	2002
4068	4068	pharmacist's licensed intern, as described in Section 58-17b-304, or licensed
4069	4069	- 59 - H.B. 543 02-21 16:04
4070	4070	2003
4071	4071	pharmacy technician, as described in Section 58-17b-305, working under the
4072	4072	2004
4073	4073	supervision of a licensed pharmacist who is also licensed to dispense a controlled
4074	4074	2005
4075	4075	substance under [Title 58, ]Chapter 37, Utah Controlled Substances Act.
4076	4076	2006
4077	4077	(b) "Outpatient" means a setting in which an individual visits a licensed healthcare
4078	4078	2007
4079	4079	facility or a healthcare provider's office for a diagnosis or treatment but is not
4080	4080	2008
4081	4081	admitted to a licensed healthcare facility for an overnight stay.
4082	4082	2009
4083	4083	(c) "Prescriber" means an individual authorized to prescribe a controlled substance under [
4084	4084	2010
4085	4085	Title 58, ]Chapter 37, Utah Controlled Substances Act.
4086	4086	2011
4087	4087	(d) "Schedule II opioid" means those substances listed in Subsection 58-37-4(2)(b)(i) or
4088	4088	2012
4089	4089	(2)(b)(ii).
4090	4090	2013
4091	4091	(e) "Schedule III opioid" means those substances listed in Subsection 58-37-4(2)(c) that
4092	4092	2014
4093	4093	are opioids.
4094	4094	2015
4095	4095	(2)(a) A prescriber shall check the database for information about a patient before the
4096	4096	2016
4097	4097	first time the prescriber gives a prescription to a patient for a Schedule II opioid or a
4098	4098	2017
4099	4099	Schedule III opioid.
4100	4100	2018
4101	4101	(b) If a prescriber is repeatedly prescribing a Schedule II opioid or Schedule III opioid to
4102	4102	2019
4103	4103	a patient, the prescriber shall periodically review information about the patient in:
4104	4104	2020
4105	4105	(i) the database; or
4106	4106	2021
4107	4107	(ii) other similar records of controlled substances the patient has filled.
4108	4108	2022
4109	4109	(c) A prescriber may assign the access and review required under Subsection (2)(a) to
4110	4110	2023
4111	4111	one or more employees in accordance with Subsections 58-37f-301(2)(i) and (j).
4112	4112	2024
4113	4113	(d)(i) A prescriber may comply with the requirements in Subsections (2)(a) and (b)
4114	4114	2025
4115	4115	by checking an electronic health record system if the electronic health record
4116	4116	2026
4117	4117	system:
4118	4118	2027
4119	4119	(A) is connected to the database through a connection that has been approved by
4120	4120	2028
4121	4121	the division; and
4122	4122	2029
4123	4123	(B) displays the information from the database in a prominent manner for the
4124	4124	2030
4125	4125	prescriber.
4126	4126	2031
4127	4127	(ii) The division may not approve a connection to the database if the connection does
4128	4128	2032
4129	4129	not satisfy the requirements established by the division under Section 58-37f-301.
4130	4130	2033
4131	4131	(e) A prescriber is not in violation of the requirements of Subsection (2)(a) or (b) if the
4132	4132	2034
4133	4133	failure to comply with Subsection (2)(a) or (b):
4134	4134	2035
4135	4135	(i) is necessary due to an emergency situation;
4136	4136	2036
4137	4137	(ii) is caused by a suspension or disruption in the operation of the database; or
4138	4138	- 60 - 02-21 16:04 H.B. 543
4139	4139	2037
4140	4140	(iii) is caused by a failure in the operation or availability of the Internet.
4141	4141	2038
4142	4142	(f) The division may not take action against the license of a prescriber for failure to
4143	4143	2039
4144	4144	comply with this Subsection (2) unless the failure occurs after the earlier of:
4145	4145	2040
4146	4146	(i) December 31, 2018; or
4147	4147	2041
4148	4148	(ii) the date that the division has the capability to establish a connection that meets
4149	4149	2042
4150	4150	the requirements established by the division under Section 58-37f-301 between
4151	4151	2043
4152	4152	the database and an electronic health record system.
4153	4153	2044
4154	4154	(3) The division shall, in collaboration with the licensing boards for prescribers and
4155	4155	2045
4156	4156	dispensers:
4157	4157	2046
4158	4158	(a) develop a system that gathers and reports to prescribers and dispensers the progress
4159	4159	2047
4160	4160	and results of the prescriber's and dispenser's individual access and review of the
4161	4161	2048
4162	4162	database, as provided in this section; and
4163	4163	2049
4164	4164	(b) reduce or waive the division's continuing education requirements regarding opioid
4165	4165	2050
4166	4166	prescriptions, described in [Section 58-37-6.5, including the online tutorial and test
4167	4167	2051
4168	4168	relating to the database] Section 58-1-605, for prescribers and dispensers whose
4169	4169	2052
4170	4170	individual utilization of the database, as determined by the division, demonstrates
4171	4171	2053
4172	4172	substantial compliance with this section.
4173	4173	2054
4174	4174	(4) If the dispenser's access and review of the database suggest that the individual seeking
4175	4175	2055
4176	4176	an opioid may be obtaining opioids in quantities or frequencies inconsistent with
4177	4177	2056
4178	4178	generally recognized standards as provided in this section and Section 58-37f-201, the
4179	4179	2057
4180	4180	dispenser shall reasonably attempt to contact the prescriber to obtain the prescriber's
4181	4181	2058
4182	4182	informed, current, and professional decision regarding whether the prescribed opioid is
4183	4183	2059
4184	4184	medically justified, notwithstanding the results of the database search.
4185	4185	2060
4186	4186	(5)(a) The division shall review the database to identify any prescriber who has a pattern
4187	4187	2061
4188	4188	of prescribing opioids not in accordance with the recommendations of:
4189	4189	2062
4190	4190	(i) the CDC Guideline for Prescribing Opioids for Chronic Pain, published by the
4191	4191	2063
4192	4192	Centers for Disease Control and Prevention;
4193	4193	2064
4194	4194	(ii) the Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain,
4195	4195	2065
4196	4196	published by the Department of Health and Human Services; or
4197	4197	2066
4198	4198	(iii) other publications describing best practices related to prescribing opioids as
4199	4199	2067
4200	4200	identified by division rule in accordance with Title 63G, Chapter 3, Utah
4201	4201	2068
4202	4202	Administrative Rulemaking Act, and in consultation with the Medical Licensing
4203	4203	2069
4204	4204	Board.
4205	4205	2070
4206	4206	(b) The division shall offer education to a prescriber identified under this Subsection (5)
4207	4207	- 61 - H.B. 543 02-21 16:04
4208	4208	2071
4209	4209	regarding best practices in the prescribing of opioids.
4210	4210	2072
4211	4211	(c) A decision by a prescriber to accept or not accept the education offered by the
4212	4212	2073
4213	4213	division under this Subsection (5) is voluntary.
4214	4214	2074
4215	4215	(d) The division may not use an identification the division has made under this
4216	4216	2075
4217	4217	Subsection (5) or the decision by a prescriber to accept or not accept education
4218	4218	2076
4219	4219	offered by the division under this Subsection (5) in a licensing investigation or action
4220	4220	2077
4221	4221	by the division.
4222	4222	2078
4223	4223	(e) Any record created by the division as a result of this Subsection (5) is a protected
4224	4224	2079
4225	4225	record under Section 63G-2-305.
4226	4226	2080
4227	4227	(6) The division may consult with a prescriber or health care system to assist the prescriber
4228	4228	2081
4229	4229	or health care system in following evidence-based guidelines regarding the prescribing
4230	4230	2082
4231	4231	of controlled substances, including the recommendations listed in Subsection (5)(a).
4232	4232	2083
4233	4233	Section 16. Section 58-37f-502 is amended to read:
4234	4234	2084
4235	4235	58-37f-502 (Effective 07/01/25). Use of dedicated credits -- Controlled Substance
4236	4236	2085
4237	4237	Database -- Collection of penalties.
4238	4238	2086
4239	4239	(1) The director may use the money deposited in the General Fund as a dedicated credit
4240	4240	2087
4241	4241	under Subsections [58-37-6(8)(a)] 58-37-6(6)(a), 58-37f-601(3)(d), and 58-37f-602(2)
4242	4242	2088
4243	4243	for the following purposes:
4244	4244	2089
4245	4245	(a) maintenance and replacement of the database equipment, including hardware and
4246	4246	2090
4247	4247	software;
4248	4248	2091
4249	4249	(b) training of staff; and
4250	4250	2092
4251	4251	(c) pursuit of external grants and matching funds.
4252	4252	2093
4253	4253	(2) The director of the division may collect any penalty imposed under Subsections [
4254	4254	2094
4255	4255	58-37-6(8)(a)] 58-37-6(6)(a), 58-37f-601(3)(d), and 58-37f-602(2) and which is not paid
4256	4256	2095
4257	4257	by:
4258	4258	2096
4259	4259	(a) referring the matter to the Office of State Debt Collection or a collection agency; or
4260	4260	2097
4261	4261	(b) bringing an action in the district court of the county in which the person owing the
4262	4262	2098
4263	4263	debt resides or in the county where the office of the director is located.
4264	4264	2099
4265	4265	(3) The director may seek legal assistance from the attorney general or the county or district
4266	4266	2100
4267	4267	attorney of the district in which the action is brought to collect the fine.
4268	4268	2101
4269	4269	(4) The court shall award reasonable attorney fees and costs to the division for successful
4270	4270	2102
4271	4271	collection actions under Subsection (2)(b).
4272	4272	2103
4273	4273	Section 17. Section 58-37f-702 is amended to read:
4274	4274	2104
4275	4275	58-37f-702 (Effective 07/01/25). Reporting prescribed controlled substance
4276	4276	- 62 - 02-21 16:04 H.B. 543
4277	4277	2105
4278	4278	poisoning or overdose to a practitioner.
4279	4279	2106
4280	4280	(1)(a) The division shall take the actions described in Subsection (1)(b) if the division
4281	4281	2107
4282	4282	receives a report from a general acute hospital under Section 26B-2-225 regarding
4283	4283	2108
4284	4284	admission to a general acute hospital for poisoning or overdose involving a
4285	4285	2109
4286	4286	prescribed controlled substance.
4287	4287	2110
4288	4288	(b) The division shall, within three business days after the day on which a report in
4289	4289	2111
4290	4290	Subsection (1)(a) is received:
4291	4291	2112
4292	4292	(i) attempt to identify, through the database, each practitioner who may have
4293	4293	2113
4294	4294	prescribed the controlled substance to the patient; and
4295	4295	2114
4296	4296	(ii) provide each practitioner identified under Subsection (1)(b)(i) with:
4297	4297	2115
4298	4298	(A) a copy of the report provided by the general acute hospital under Section
4299	4299	2116
4300	4300	26B-2-225; and
4301	4301	2117
4302	4302	(B) the information obtained from the database that led the division to determine
4303	4303	2118
4304	4304	that the practitioner receiving the information may have prescribed the
4305	4305	2119
4306	4306	controlled substance to the person named in the report.
4307	4307	2120
4308	4308	(2)(a) When the division receives a report from the medical examiner under Section
4309	4309	2121
4310	4310	26B-8-210 regarding a death caused by poisoning or overdose involving a prescribed
4311	4311	2122
4312	4312	controlled substance, for each practitioner identified by the medical examiner under
4313	4313	2123
4314	4314	Subsection 26B-8-210(1)(c), the division:
4315	4315	2124
4316	4316	(i) shall, within five business days after the day on which the division receives the
4317	4317	2125
4318	4318	report, provide the practitioner with a copy of the report; and
4319	4319	2126
4320	4320	(ii) may offer the practitioner an educational visit to review the report.
4321	4321	2127
4322	4322	(b) A practitioner may decline an educational visit described in Subsection (2)(a)(ii).
4323	4323	2128
4324	4324	(c) The division may not use, in a licensing investigation or action by the division:
4325	4325	2129
4326	4326	(i) information from an educational visit described in Subsection (2)(a)(ii); or
4327	4327	2130
4328	4328	(ii) a practitioner's decision to decline an educational visit described in Subsection
4329	4329	2131
4330	4330	(2)(a)(ii).
4331	4331	2132
4332	4332	(3) It is the intent of the Legislature that the information provided under Subsection (1) or
4333	4333	2133
4334	4334	(2) is provided for the purpose of assisting the practitioner in:
4335	4335	2134
4336	4336	(a) discussing with the patient or others issues relating to the poisoning or overdose;
4337	4337	2135
4338	4338	(b) advising the patient or others of measures that may be taken to avoid a future
4339	4339	2136
4340	4340	poisoning or overdose; and
4341	4341	2137
4342	4342	(c) making decisions regarding future prescriptions written for the patient or others.
4343	4343	2138
4344	4344	(4) Any record created by the division as a result of an educational visit described in
4345	4345	- 63 - H.B. 543 02-21 16:04
4346	4346	2139
4347	4347	Subsection (2)(a)(ii) is a protected record for purposes of Title 63G, Chapter 2,
4348	4348	2140
4349	4349	Government Records Access and Management Act.
4350	4350	2141
4351	4351	[(5) Beginning on July 1, 2010, the division shall, in accordance with Section 63J-1-504,
4352	4352	2142
4353	4353	increase the licensing fee described in Subsection 58-37-6(1)(b) to pay the startup and
4354	4354	2143
4355	4355	ongoing costs of the division for complying with the requirements of this section.]
4356	4356	2144
4357	4357	Section 18. Section 58-37f-703 is amended to read:
4358	4358	2145
4359	4359	58-37f-703 (Effective 07/01/25). Entering certain convictions into the database
4360	4360	2146
4361	4361	and reporting them to practitioners.
4362	4362	2147
4363	4363	(1) When the division receives a report from a court under Subsection 41-6a-502(5) or
4364	4364	2148
4365	4365	41-6a-502.5(5)(b) relating to a conviction for driving under the influence of, or while
4366	4366	2149
4367	4367	impaired by, a prescribed controlled substance, the division shall:
4368	4368	2150
4369	4369	(a) daily enter into the database the information supplied in the report, including the date
4370	4370	2151
4371	4371	on which the person was convicted;
4372	4372	2152
4373	4373	(b) attempt to identify, through the database, each practitioner who may have prescribed
4374	4374	2153
4375	4375	the controlled substance to the convicted person; and
4376	4376	2154
4377	4377	(c) provide each practitioner identified under Subsection (1)(b) with:
4378	4378	2155
4379	4379	(i) a copy of the information provided by the court; and
4380	4380	2156
4381	4381	(ii) the information obtained from the database that led the division to determine that
4382	4382	2157
4383	4383	the practitioner receiving the information may have prescribed the controlled
4384	4384	2158
4385	4385	substance to the convicted person.
4386	4386	2159
4387	4387	(2) It is the intent of the Legislature that the information provided under Subsection (1)(b)
4388	4388	2160
4389	4389	is provided for the purpose of assisting the practitioner in:
4390	4390	2161
4391	4391	(a) discussing the manner in which the controlled substance may impact the convicted
4392	4392	2162
4393	4393	person's driving;
4394	4394	2163
4395	4395	(b) advising the convicted person on measures that may be taken to avoid adverse
4396	4396	2164
4397	4397	impacts of the controlled substance on future driving; and
4398	4398	2165
4399	4399	(c) making decisions regarding future prescriptions written for the convicted person.
4400	4400	2166
4401	4401	[(3) Beginning on July 1, 2010, the division shall, in accordance with Section 63J-1-504,
4402	4402	2167
4403	4403	increase the licensing fee described in Subsection 58-37-6(1)(b) to pay the startup and
4404	4404	2168
4405	4405	ongoing costs of the division for complying with the requirements of this section.]
4406	4406	2169
4407	4407	Section 19. Section 63I-1-258 is amended to read:
4408	4408	2170
4409	4409	63I-1-258 (Effective 07/01/25). Repeal dates: Title 58.
4410	4410	2171
4411	4411	(1) Title 58, Chapter 13, Health Care Providers Immunity from Liability Act, is repealed
4412	4412	2172
4413	4413	July 1, 2026.
4414	4414	- 64 - 02-21 16:04 H.B. 543
4415	4415	2173
4416	4416	(2) Title 58, Chapter 15, Health Facility Administrator Act, is repealed July 1, 2025.
4417	4417	2174
4418	4418	(3) Title 58, Chapter 20b, Environmental Health Scientist Act, is repealed July 1, 2028.
4419	4419	2175
4420	4420	(4) Section 58-37-3.5, Drugs for behavioral health treatment, is repealed July 1, 2027.
4421	4421	2176
4422	4422	(5) Subsection [58-37-6(7)(f)(iii)] 58-37-6(5)(f)(iii), regarding a seven-day opiate supply
4423	4423	2177
4424	4424	restriction, is repealed July 1, 2032.
4425	4425	2178
4426	4426	(6) Title 58, Chapter 40, Recreational Therapy Practice Act, is repealed July 1, 2033.
4427	4427	2179
4428	4428	(7) Title 58, Chapter 41, Speech-Language Pathology and Audiology Licensing Act, is
4429	4429	2180
4430	4430	repealed July 1, 2029.
4431	4431	2181
4432	4432	(8) Title 58, Chapter 46a, Hearing Instrument Specialist Licensing Act, is repealed July 1,
4433	4433	2182
4434	4434	2033.
4435	4435	2183
4436	4436	(9) Title 58, Chapter 47b, Massage Therapy Practice Act, is repealed July 1, 2034.
4437	4437	2184
4438	4438	(10) Subsection 58-55-201(2), regarding the Alarm System and Security Licensing
4439	4439	2185
4440	4440	Advisory Board, is repealed July 1, 2027.
4441	4441	2186
4442	4442	(11) Title 58, Chapter 61, Part 7, Behavior Analyst Licensing Act, is repealed July 1, 2026.
4443	4443	2187
4444	4444	Section 20. Section 76-5-102.1 is amended to read:
4445	4445	2188
4446	4446	76-5-102.1 (Effective 07/01/25). Negligently operating a vehicle resulting in
4447	4447	2189
4448	4448	injury.
4449	4449	2190
4450	4450	(1)(a) As used in this section:
4451	4451	2191
4452	4452	(i) "Controlled substance" means the same as that term is defined in Section 58-37-2.
4453	4453	2192
4454	4454	(ii) "Drug" means the same as that term is defined in Section 76-5-207.
4455	4455	2193
4456	4456	(iii) "Negligent" or "negligence" means the same as that term is defined in Section
4457	4457	2194
4458	4458	76-5-207.
4459	4459	2195
4460	4460	(iv) "Vehicle" means the same as that term is defined in Section 41-6a-501.
4461	4461	2196
4462	4462	(b) Terms defined in Section 76-1-101.5 apply to this section.
4463	4463	2197
4464	4464	(2) An actor commits negligently operating a vehicle resulting in injury if the actor:
4465	4465	2198
4466	4466	(a)(i) operates a vehicle in a negligent manner causing bodily injury to another; and
4467	4467	2199
4468	4468	(ii)(A) has sufficient alcohol in the actor's body such that a subsequent chemical
4469	4469	2200
4470	4470	test shows that the actor has a blood or breath alcohol concentration of .05
4471	4471	2201
4472	4472	grams or greater at the time of the test;
4473	4473	2202
4474	4474	(B) is under the influence of alcohol, a drug, or the combined influence of alcohol
4475	4475	2203
4476	4476	and a drug to a degree that renders the actor incapable of safely operating a
4477	4477	2204
4478	4478	vehicle; or
4479	4479	2205
4480	4480	(C) has a blood or breath alcohol concentration of .05 grams or greater at the time
4481	4481	2206
4482	4482	of operation; or
4483	4483	- 65 - H.B. 543 02-21 16:04
4484	4484	2207
4485	4485	(b)(i) operates a vehicle in a criminally negligent manner causing bodily injury to
4486	4486	2208
4487	4487	another; and
4488	4488	2209
4489	4489	(ii) has in the actor's body any measurable amount of a controlled substance.
4490	4490	2210
4491	4491	(3) Except as provided in Subsection (4), a violation of Subsection (2) is:
4492	4492	2211
4493	4493	(a)(i) a class A misdemeanor; or
4494	4494	2212
4495	4495	(ii) a third degree felony if the actor has two or more driving under the influence
4496	4496	2213
4497	4497	related convictions under Subsection 41-6a-501(2)(a), each of which is within 10
4498	4498	2214
4499	4499	years of:
4500	4500	2215
4501	4501	(A) the current conviction; or
4502	4502	2216
4503	4503	(B) the commission of the offense upon which the current conviction is based;
4504	4504	2217
4505	4505	(iii) a third degree felony, if the current conviction is at any time after the conviction
4506	4506	2218
4507	4507	of:
4508	4508	2219
4509	4509	(A) a conviction, as the term conviction is defined in Subsection 41-6a-501(2),
4510	4510	2220
4511	4511	that is a felony; or
4512	4512	2221
4513	4513	(B) any conviction described in Subsection (3)(a)(iii)(A) for which judgment of
4514	4514	2222
4515	4515	conviction is reduced under Section 76-3-402; or
4516	4516	2223
4517	4517	(iv) a third degree felony if the bodily injury is serious bodily injury; and
4518	4518	2224
4519	4519	(b) a separate offense for each victim suffering bodily injury as a result of the actor's
4520	4520	2225
4521	4521	violation of this section, regardless of whether the injuries arise from the same
4522	4522	2226
4523	4523	episode of driving.
4524	4524	2227
4525	4525	(4) An actor is not guilty of negligently operating a vehicle resulting in injury under
4526	4526	2228
4527	4527	Subsection (2)(b) if:
4528	4528	2229
4529	4529	(a) the controlled substance was obtained under a valid prescription or order, directly
4530	4530	2230
4531	4531	from a practitioner while acting in the course of the practitioner's professional
4532	4532	2231
4533	4533	practice, or as otherwise authorized by Title 58, Occupations and Professions;
4534	4534	2232
4535	4535	(b) the controlled substance is 11-nor-9-carboxy-tetrahydrocannabinol; or
4536	4536	2233
4537	4537	(c) the actor possessed, in the actor's body, a controlled substance listed in Section
4538	4538	2234
4539	4539	58-37-4.2 if:
4540	4540	2235
4541	4541	(i) the actor is the subject of medical research conducted by a holder of a valid [
4542	4542	2236
4543	4543	license to possess controlled substances under Section 58-37-6] registration issued
4544	4544	2237
4545	4545	by the federal Drug Enforcement Administration; and
4546	4546	2238
4547	4547	(ii) the substance was administered to the actor by the medical researcher.
4548	4548	2239
4549	4549	(5)(a) A judge imposing a sentence under this section may consider:
4550	4550	2240
4551	4551	(i) the adult sentencing and supervision length guidelines, as defined in Section
4552	4552	- 66 - 02-21 16:04 H.B. 543
4553	4553	2241
4554	4554	63M-7-401.1;
4555	4555	2242
4556	4556	(ii) the defendant's history;
4557	4557	2243
4558	4558	(iii) the facts of the case;
4559	4559	2244
4560	4560	(iv) aggravating and mitigating factors; or
4561	4561	2245
4562	4562	(v) any other relevant fact.
4563	4563	2246
4564	4564	(b) The judge may not impose a lesser sentence than would be required for a conviction
4565	4565	2247
4566	4566	based on the defendant's history under Section 41-6a-505.
4567	4567	2248
4568	4568	(c) The standards for chemical breath analysis under Section 41-6a-515 and the
4569	4569	2249
4570	4570	provisions for the admissibility of chemical test results under Section 41-6a-516
4571	4571	2250
4572	4572	apply to determination and proof of blood alcohol content under this section.
4573	4573	2251
4574	4574	(d) A calculation of blood or breath alcohol concentration under this section shall be
4575	4575	2252
4576	4576	made in accordance with Subsection 41-6a-502(3).
4577	4577	2253
4578	4578	(e) Except as provided in Subsection (4), the fact that an actor charged with violating
4579	4579	2254
4580	4580	this section is or has been legally entitled to use alcohol or a drug is not a defense.
4581	4581	2255
4582	4582	(f) Evidence of a defendant's blood or breath alcohol content or drug content is
4583	4583	2256
4584	4584	admissible except if prohibited by the Utah Rules of Evidence, the United States
4585	4585	2257
4586	4586	Constitution, or the Utah Constitution.
4587	4587	2258
4588	4588	(g) In accordance with Subsection 77-2a-3(8), a guilty or no contest plea to an offense
4589	4589	2259
4590	4590	described in this section may not be held in abeyance.
4591	4591	2260
4592	4592	Section 21. Section 76-5-207 is amended to read:
4593	4593	2261
4594	4594	76-5-207 (Effective 07/01/25). Automobile homicide -- Penalties -- Evidence.
4595	4595	2262
4596	4596	(1)(a) As used in this section:
4597	4597	2263
4598	4598	(i) "Controlled substance" means the same as that term is defined in Section 58-37-2.
4599	4599	2264
4600	4600	(ii) "Criminally negligent" means the same as that term is described in Subsection
4601	4601	2265
4602	4602	76-2-103(4).
4603	4603	2266
4604	4604	(iii) "Drug" means:
4605	4605	2267
4606	4606	(A) a controlled substance;
4607	4607	2268
4608	4608	(B) a drug as defined in Section 58-37-2; or
4609	4609	2269
4610	4610	(C) a substance that, when knowingly, intentionally, or recklessly taken into the
4611	4611	2270
4612	4612	human body, can impair the ability of an individual to safely operate a vehicle.
4613	4613	2271
4614	4614	(iv) "Negligent" or "negligence" means simple negligence, the failure to exercise that
4615	4615	2272
4616	4616	degree of care that reasonable and prudent persons exercise under like or similar
4617	4617	2273
4618	4618	circumstances.
4619	4619	2274
4620	4620	(v) "Vehicle" means the same as that term is defined in Section 41-6a-501.
4621	4621	- 67 - H.B. 543 02-21 16:04
4622	4622	2275
4623	4623	(b) Terms defined in Section 76-1-101.5 apply to this section.
4624	4624	2276
4625	4625	(2) An actor commits automobile homicide if the actor:
4626	4626	2277
4627	4627	(a)(i) operates a vehicle in a negligent or criminally negligent manner causing the
4628	4628	2278
4629	4629	death of another individual; and
4630	4630	2279
4631	4631	(ii)(A) has sufficient alcohol in the actor's body such that a subsequent chemical
4632	4632	2280
4633	4633	test shows that the actor has a blood or breath alcohol concentration of .05
4634	4634	2281
4635	4635	grams or greater at the time of the test;
4636	4636	2282
4637	4637	(B) is under the influence of alcohol, any drug, or the combined influence of
4638	4638	2283
4639	4639	alcohol and any drug to a degree that renders the actor incapable of safely
4640	4640	2284
4641	4641	operating a vehicle; or
4642	4642	2285
4643	4643	(C) has a blood or breath alcohol concentration of .05 grams or greater at the time
4644	4644	2286
4645	4645	of operation; or
4646	4646	2287
4647	4647	(b)(i) operates a vehicle in a criminally negligent manner causing death to another;
4648	4648	2288
4649	4649	and
4650	4650	2289
4651	4651	(ii) has in the actor's body any measurable amount of a controlled substance.
4652	4652	2290
4653	4653	(3) Except as provided in Subsection (4), an actor who violates Subsection (2) is guilty of:
4654	4654	2291
4655	4655	(a) a second degree felony, punishable by a term of imprisonment of not less than five
4656	4656	2292
4657	4657	years nor more than 15 years; and
4658	4658	2293
4659	4659	(b) a separate offense for each victim suffering death as a result of the actor's violation
4660	4660	2294
4661	4661	of this section, regardless of whether the deaths arise from the same episode of
4662	4662	2295
4663	4663	driving.
4664	4664	2296
4665	4665	(4) An actor is not guilty of a violation of automobile homicide under Subsection (2)(b) if:
4666	4666	2297
4667	4667	(a) the controlled substance was obtained under a valid prescription or order, directly
4668	4668	2298
4669	4669	from a practitioner while acting in the course of the practitioner's professional
4670	4670	2299
4671	4671	practice, or as otherwise authorized by Title 58, Occupations and Professions;
4672	4672	2300
4673	4673	(b) the controlled substance is 11-nor-9-carboxy-tetrahydrocannabinol; or
4674	4674	2301
4675	4675	(c) the actor possessed, in the actor's body, a controlled substance listed in Section
4676	4676	2302
4677	4677	58-37-4.2 if:
4678	4678	2303
4679	4679	(i) the actor is the subject of medical research conducted by a holder of a valid [
4680	4680	2304
4681	4681	license to possess controlled substances under Section 58-37-6] registration issued
4682	4682	2305
4683	4683	by the federal Drug Enforcement Administration; and
4684	4684	2306
4685	4685	(ii) the substance was administered to the actor by the medical researcher.
4686	4686	2307
4687	4687	(5)(a) A judge imposing a sentence under this section may consider:
4688	4688	2308
4689	4689	(i) the adult sentencing and supervision length guidelines, as defined in Section
4690	4690	- 68 - 02-21 16:04 H.B. 543
4691	4691	2309
4692	4692	63M-7-401.1;
4693	4693	2310
4694	4694	(ii) the defendant's history;
4695	4695	2311
4696	4696	(iii) the facts of the case;
4697	4697	2312
4698	4698	(iv) aggravating and mitigating factors; or
4699	4699	2313
4700	4700	(v) any other relevant fact.
4701	4701	2314
4702	4702	(b) The judge may not impose a lesser sentence than would be required for a conviction
4703	4703	2315
4704	4704	based on the defendant's history under Section 41-6a-505.
4705	4705	2316
4706	4706	(c) The standards for chemical breath analysis as provided by Section 41-6a-515 and the
4707	4707	2317
4708	4708	provisions for the admissibility of chemical test results as provided by Section
4709	4709	2318
4710	4710	41-6a-516 apply to determination and proof of blood alcohol content under this
4711	4711	2319
4712	4712	section.
4713	4713	2320
4714	4714	(d) A calculation of blood or breath alcohol concentration under this section shall be
4715	4715	2321
4716	4716	made in accordance with Subsection 41-6a-502(3).
4717	4717	2322
4718	4718	(e) Except as provided in Subsection (4), the fact that an actor charged with violating
4719	4719	2323
4720	4720	this section is or has been legally entitled to use alcohol or a drug is not a defense.
4721	4721	2324
4722	4722	(f) Evidence of a defendant's blood or breath alcohol content or drug content is
4723	4723	2325
4724	4724	admissible except when prohibited by the Utah Rules of Evidence, the United States
4725	4725	2326
4726	4726	Constitution, or the Utah Constitution.
4727	4727	2327
4728	4728	(g) In accordance with Subsection 77-2a-3(8), a guilty or no contest plea to an offense
4729	4729	2328
4730	4730	described in this section may not be held in abeyance.
4731	4731	2329
4732	4732	(6) If, when imposing a sentence under this section, the court finds that it is in the interest
4733	4733	2330
4734	4734	of justice to suspend the imposition of prison, the court shall detail the finding on the
4735	4735	2331
4736	4736	record, including why a suspended prison sentence is in the interest of justice.
4737	4737	2332
4738	4738	(7) Notwithstanding Subsection (3)(a), the court may impose a sentence of not less than
4739	4739	2333
4740	4740	three years nor more than 15 years if the court details on the record why it is in the
4741	4741	2334
4742	4742	interest of justice.
4743	4743	2335
4744	4744	Section 22. Repealer.
4745	4745	2336
4746	4746	This bill repeals:
4747	4747	2337
4748	4748	Section 26B-3-131, Screening, Brief Intervention, and Referral to Treatment Medicaid
4749	4749	2338
4750	4750	reimbursement.
4751	4751	2339
4752	4752	Section 49-20-416, Screening, Brief Intervention, and Referral to Treatment program
4753	4753	2340
4754	4754	reimbursement.
4755	4755	2341
4756	4756	Section 58-37-6.5, Continuing education for controlled substance prescribers.
4757	4757	2342
4758	4758	Section 23. Effective Date.
4759	4759	- 69 - H.B. 543 02-21 16:04
4760	4760	2343
4761	4761	(1) Except as provided in Subsection (2), this bill takes effect July 1, 2025.
4762	4762	2344
4763	4763	(2) The actions affecting Section 58-1-605 (Effective 05/07/25) take effect on May 7, 2025.
4764	4764	- 70 -